


HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2024 OF THE CONDITION AND AFFAIRS OF THE

Molina Healthcare of Iowa, Inc.

NAIC G	Group Code <u>1531</u> 1531 NA	IC Company Code 17197 Emp	ployer's ID Number38-4187674
Organized under the Laws of	(Current) (Prior) Lowa		Port of EntryIA
Country of Domicile		United States of America	
Licensed as business type:		Health Maintenance Organization	
Is HMO Federally Qualified? Y	es[]No[X]		
Incorporated/Organized	12/28/2021	Commenced Busin	iness07/01/2023
Statutory Home Office	500 SW 7th St, Suite 304		Des Moines, IA, US 50309
Main Administrative Office	(Street and Number)	Caraca Caracaca See Nome Secon	(City or Town, State, Country and Zip Code)
		500 SW 7th St, Suite 304 (Street and Number)	
	Des Moines, IA, US 50309		562-542-1935
	own, State, Country and Zip Code)		(Area Code) (Telephone Number)
Mail Address	500 SW 7th St, Suite 304		Des Moines, IA, US 50309
	(Street and Number or P.O. Box)		(City or Town, State, Country and Zip Code)
Primary Location of Books and F	Records	500 SW 7th St, Suite 304	
ī	Des Moines, IA, US 50309	(Street and Number)	702 Lau 2, 1987/000
(City or T	own, State, Country and Zip Code)		562-542-1935 (Area Code) (Telephone Number)
Internet Website Address			(130 300) (Telephone Number)
	W. Jr. Marketon in	www.molinahealthcare.com	
Statutory Statement Contact _	Aarati M Mehta		614-540-3488
aarati	(Name) mehta@molinahealthcare.com		(Area Code) (Telephone Number)
	(E-mail Address)		(FAX Number)
		OFFICERS	•
President	Jennifer Hansen Vermeer		retary
Chief Financial Officer	Joan Gwen Noddings		Jelliey Doll Ballow
		OTHER	
		UINER	
Jennifer Hanse	on Vermeer	RECTORS OR TRUSTEES	
	ar vermeer	David Thomas Reynolds	Ronald Douglas Kurtz
State of	lowa		
County of	Des Moines SS		
statement, together with related condition and affairs of the said in accordance with the NAIC An rules or regulations require diffrespectively. Furthermore, the sexact copy (except for formatting o the enclosed statement.	exhibits, schedules and explanations there eporting entity as of the reporting period sinual Statement Instructions and Accountierences in reporting not related to accope of this attestation by the described differences due to electronic filing) of the	in contained, annexed or referred to, is tated above, and of its income and ded ng Practices and Procedures manual of punting practices and procedures, ac	said reporting entity, and that on the reporting period stated any liens or claims thereon, except as herein stated, and that is a full and true statement of all the assets and liabilities and ductions therefrom for the period ended, and have been compexcept to the extent that: (1) state law may differ; or, (2) that coording to the best of their information, knowledge and besponding electronic filing with the NAIC, when required, that ling may be requested by various regulators in lieu of or in ad-
Jennifer Hansen Ve President	rmeer	Joan Gwen Noddings	Jeffrey Don Barlow
i roodent		Chief Financial Officer	Secretary
Subscribed and sworn to before a day of	ne this Flory any	b. If no, 1. State the ar 2. Date filed	inal filing?





HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2024 OF THE CONDITION AND AFFAIRS OF THE

Molina Healthcare of Iowa, Inc.

NAIC Grou		Company Code	17197	umber <u>38-4187674</u>
Organized under the Laws of	(Current) (Prior) lowa	, Sta	te of Domicile or Port of Entry	<u>IA</u>
Country of Domicile		United States of	America	
Licensed as business type:	Hea	Ith Maintenance	Organization	
Is HMO Federally Qualified? Yes	[] No [X]			
Incorporated/Organized	12/28/2021		Commenced Business	07/01/2023
Statutory Home Office	500 SW 7th St, Suite 304			es Moines, IA, US 50309
	(Street and Number)		, ,	own, State, Country and Zip Code)
Main Administrative Office		500 SW 7th St, S (Street and Nu		
	s Moines, IA, US 50309 n, State, Country and Zip Code)			562-542-1935 a Code) (Telephone Number)
			,	
Mail Address	500 SW 7th St, Suite 304 (Street and Number or P.O. Box)	,		ves Moines, IA, US 50309 own, State, Country and Zip Code)
Primary Location of Books and Rec	cords	500 SW 7th St, 5	Suite 304	
•		(Street and Nu	mber)	ECO 540 4025
	s Moines, IA, US 50309 n, State, Country and Zip Code)		(Area	562-542-1935 a Code) (Telephone Number)
Internet Website Address	W	ww.molinahealth	care.com	
Statutory Statement Contact	Aarati M Mehta		,	614-540-3488
aarati me	(Name) ehta@molinahealthcare.com			(Area Code) (Telephone Number)
darattan	(E-mail Address)			(FAX Number)
		OFFICER	RS	
	Jennifer Hansen Vermeer		Secretary	Jeffrey Don Barlow
Chief Financial Officer	Joan Gwen Noddings			
		OTHER		
	DIR	ECTORS OR T	RUSTEES	
Jennifer Hansen	Vermeer	David Thomas I	Reynolds	Ronald Douglas Kurtz
State of	lowa			
	Des Moines SS			
all of the herein described assets statement, together with related ex condition and affairs of the said reg in accordance with the NAIC Annurules or regulations require differ respectively. Furthermore, the sco	were the absolute property of the said re hibits, schedules and explanations therein oorting entity as of the reporting period stat all Statement Instructions and Accounting ences in reporting not related to account ope of this attestation by the described offi	porting entity, fre contained, anner ed above, and of Practices and Practices are rices a sicers also include	ee and clear from any liens or ked or referred to, is a full and its income and deductions the rocedures manual except to the and procedures, according to the sthe related corresponding e	ing entity, and that on the reporting period stated above, claims thereon, except as herein stated, and that this true statement of all the assets and liabilities and of the erefrom for the period ended, and have been completed ne extent that: (1) state law may differ; or, (2) that state in the best of their information, knowledge and belief, electronic filing with the NAIC, when required, that is an exequested by various regulators in lieu of or in addition
Jennifer Hansen Verm President	neer	Joan Gwen No Chief Financial	()	Jeffrey Don Barlow Secretary
	e this January 2025 1 Noddings (only)		a. Is this an original filing? b. If no, 1. State the amendment 2. Date filed	number

NOTARIAL OF THE KELLY SANDERS NOTARY PUBLIC for the STATE OF MONTANA Residing at Billings, Montana My Commission Expires August 28, 2028

ASSETS

i			Current Year		Prior Year
		1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1.	Bonds (Schedule D)	81,827,577		81,827,577	
	Stocks (Schedule D):				
	2.1 Preferred stocks				
	2.2 Common stocks				
3.	Mortgage loans on real estate (Schedule B):				
	3.1 First liens				
	3.2 Other than first liens				
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$				
	encumbrances)				
	4.2 Properties held for the production of income (less				
	\$ encumbrances)				
	4.3 Properties held for sale (less \$				
	encumbrances)				
5.	Cash (\$ 59,531,661 , Schedule E - Part 1), cash equivalents				
	(\$132,107,295 , Schedule E - Part 2) and short-term				
	investments (\$, Schedule DA)	191,638,956		191,638,956	210,870,517
6.	Contract loans, (including \$ premium notes)				
	Derivatives (Schedule DB)				
8.	Other invested assets (Schedule BA)				
	Receivables for securities				
	Securities lending reinvested collateral assets (Schedule DL)				
	Aggregate write-ins for invested assets				
12.	Subtotals, cash and invested assets (Lines 1 to 11)	273,466,533		273,466,533	210,870,517
13.	Title plants less \$ charged off (for Title insurers				
	only)				
14.	Investment income due and accrued	1,381,323		1,381,323	923,419
15.	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection	49,854,539		49,854,539	20,482,190
	15.2 Deferred premiums, agents' balances and installments booked but				
	deferred and not yet due (including \$				
	earned but unbilled premiums)				
	15.3 Accrued retrospective premiums (\$				
	contracts subject to redetermination (\$34,848,177)			34 , 848 , 177	9,327,974
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers				
	16.2 Funds held by or deposited with reinsured companies				
	16.3 Other amounts receivable under reinsurance contracts				
17.	Amounts receivable relating to uninsured plans				
18.1	Current federal and foreign income tax recoverable and interest thereon				
18.2	Net deferred tax asset	4,383,055		4,383,055	
19.	Guaranty funds receivable or on deposit				
20.	Electronic data processing equipment and software				
21.	Furniture and equipment, including health care delivery assets				
	(\$)				
22.	Net adjustment in assets and liabilities due to foreign exchange rates				
	Receivables from parent, subsidiaries and affiliates				
24.	Health care (\$5,469,809) and other amounts receivable	18,954,126	13,484,317	5,469,809	612,695
25.	Aggregate write-ins for other-than-invested assets	947,398	947,398		
26.	Total assets excluding Separate Accounts, Segregated Accounts and	004 054 007	14 050 571	000 400 400	040 040 705
07	Protected Cell Accounts (Lines 12 to 25)	364,034,007	14,000,071	309,403,430	242,210,790
	From Separate Accounts, Segregated Accounts and Protected Cell Accounts				
	Total (Lines 26 and 27)	384,054,007	14,650,571	369,403,436	242,216,795
	DETAILS OF WRITE-INS				
1101.					
1102.					
1103.					
1198.	Summary of remaining write-ins for Line 11 from overflow page				
	Totals (Lines 1101 through 1103 plus 1198)(Line 11 above)				
2501.	Prepaids, deposits, and other assets	947,398	947,398		
2502.					
2503.					
2598.	Summary of remaining write-ins for Line 25 from overflow page				
2599.	Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)	947,398	947,398		

LIABILITIES, CAPITAL AND SURPLUS

1		LIADILITILO, CAF	, ,			Drier Veer
Claims unpaid (lites 5		<u> </u>	1 1	Current Year	2	Prior Year
1. Clare surgest (see S renewance seeds)			'	2	3	4
2. A Constant mention in control pool and brance amounts. 11,387,783 94,395 11,327,785 1,490 11,327,785 1,49			Covered	Uncovered	Total	Total
2. A Caused meetical incentive pool and bornous amounts. 11,397,753 1,395 3,490 1,1022 4. A Aggregate health policy reserves, including the lability of \$ 1.022 5. S. To meetical tools not retain the policy reserves. Producting the lability of \$ 1.022 6. Proportylassasity incention of portions received tools not retain per the public of the property	1	Claims unnaid (less \$ reinsurance ceded)	145 402 412		145 402 412	154 050 190
3. Unpaid claims adjustment experiess						
4. Agropage health protey searce, including the isolative of S or for motical lose ratio nobele per the Public Health Service Act						
\$ for resolucil lose ratio nebate part the Public Hotalt Service Act 5. Aggregate file policy reserves. 6. Proporty casually uncerned grown reserves. 7. Aggregate health claim reserves. 8. Permitter serviced as advance. 9. General expenses also a cacuad. 10. Curron festicating \$ on realized dealter gains (losses) 8 ,000,017 8 ,000,017 8 ,000,017 250, 102 10. Lost ordered as liability. 10. Celed retireurance permitten payable. 10. Amounts withhold or intended for the account of others. 10. Residence of an element of the account of others. 11. Residence of an element of the account of others. 12. Amounts withhold or intended for the account of others. 13. Residence of an element of the account of others. 14. Borrowed money (including \$	3.	Unpaid claims adjustment expenses	943,343		943,343	1,022,522
Health Serice Act	4.	Aggregate health policy reserves, including the liability of				
Health Serice Act		\$ for medical loss ratio rebate per the Public				
5. Agroyage for policy reservoirs		·				
6. Propertyceusally unesersed premium reserves. 7. Aggraphe health dain reserves. 8. Permiums received in siderance. 9. Centred expenses due or accrued. 19.434.012 19.434.012 3.033. 10. Current fotoral and foreign incorre tax payable and inferest thereon (including 3 including 3 including 3 including 3 including 3 including 4 including 4 including 4 including 4 including 5 including 6 including 6 including 6 including 6 including 6 including 7 including 8 including 6 including 7 including 8 including 9 in						
7. Agregate health claim reserves.	5.					
8. Permitures colored in advance	6.	Property/casualty unearned premium reserves				
8. Permitures colored in advance	7.	Aggregate health claim reserves				
9 General expresses the or accrued 19,434,012 19,434,012 3,003, 003, 103, 103, 103, 103, 103, 10						
10.1 Current federal and risongs income tax poyable and interest therecon (including) \$						
Oricituding S	9.	General expenses due or accrued	19,434,012		19,434,012	3,003,391
10.2 Net deferred tax fability	10.1	Current federal and foreign income tax payable and interest thereon				
10.2 Net deferred tax fability		(including \$ on realized capital gains (losses))	8,026,017		8,026,017	290,644
1.1 Ceded reinsurance premiums payable	10.2					
12		,				
1.3. Remittances and tens not allocated.	11.	Ceded reinsurance premiums payable				
14. Borrowed maney (including \$ current) and interest thereon \$ current).	12.	Amounts withheld or retained for the account of others				
Interest thereon S	13.	Remittances and items not allocated				
Interest thereon S	14	Borrowed money (including \$ current) and				
S	17.					
15. Amounts due to parent, subsidiaries and affiliates		interest thereon \$ (including				
16. Derivatives		\$ current)				
17. Payable for securities lending	15.	Amounts due to parent, subsidiaries and affiliates	4,947,673		4,947,673	5,937,240
17. Payable for securities lending	16	Derivatives				
18. Payable for securities lending 19. Funds held under reinsurance treatiles (with \$ authorized reinsurance treatiles (with \$ authorized reinsurance in unauthorized and certified (\$ 20.						
19. Funds held under reinsurance treatles (with \$	17.	·				
authorized reinsurers, \$ unauthorized reinsurers, \$ certified reinsurers and \$ certified (s) companies	18.	Payable for securities lending				
reinsurers and \$ certified reinsurers) 20. Reinsurance in unsultorized and certified (\$) companies 21. Net adjustments in assets and liabilities due to foreign exchange rates 22. Liability for amounts held under uninsured plans 23. Aggregate write-ins for other liabilities (including \$ 156,250 current). 24. Total liabilities (Lines 1 to 23) 25. Aggregate write-ins for special surplus funds 26. Common capital stock. 27. Preferred capital stock. 28. Gross paid in and contributed surplus. 29. Surplus notes. 30. Aggregate write-ins for other-than-special surplus funds. 20. Surplus notes. 31. Unassigned funds (surplus). 32. Less treasury stock, at cost: 32.1. shares preferred (value included in Line 26 \$ \$)) 32. Less preasury stock, at cost: 32. shares preferred (value included in Line 27 \$ \$)) 33. Total idepital and surplus (Lines 24 and 33) 230. Aggregate vrite-ins for other-than-special surplus funds. 231. Total liabilities, capital and surplus (Lines 24 and 33) 232. shares preferred (value included in Line 27 \$ \$)) 33. Total capital and surplus (Lines 24 and 33) 234. Total liabilities, capital and surplus (Lines 24 and 33) 235. Finas and penal ties 2301. Amounts due to government agencies 2303. Finas and penal ties 2304. Finas and penal ties 2305. Finas and penal ties 2307. Total (Lines 2301 through 2303 plus 2398)(Line 23 above) 2308. Summary of remaining write-ins for Line 23 from overflow page 2399. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above) 2309. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above) 2300. XXX 2300. XX	19.	Funds held under reinsurance treaties (with \$				
reinsurers and \$ certified reinsurers) 20. Reinsurance in unsultorized and certified (\$) companies 21. Net adjustments in assets and liabilities due to foreign exchange rates 22. Liability for amounts held under uninsured plans 23. Aggregate write-ins for other liabilities (including \$ 156,250 current). 24. Total liabilities (Lines 1 to 23) 25. Aggregate write-ins for special surplus funds 26. Common capital stock. 27. Preferred capital stock. 28. Gross paid in and contributed surplus. 29. Surplus notes. 30. Aggregate write-ins for other-than-special surplus funds. 20. Surplus notes. 31. Unassigned funds (surplus). 32. Less treasury stock, at cost: 32.1. shares preferred (value included in Line 26 \$ \$)) 32. Less preasury stock, at cost: 32. shares preferred (value included in Line 27 \$ \$)) 33. Total idepital and surplus (Lines 24 and 33) 230. Aggregate vrite-ins for other-than-special surplus funds. 231. Total liabilities, capital and surplus (Lines 24 and 33) 232. shares preferred (value included in Line 27 \$ \$)) 33. Total capital and surplus (Lines 24 and 33) 234. Total liabilities, capital and surplus (Lines 24 and 33) 235. Finas and penal ties 2301. Amounts due to government agencies 2303. Finas and penal ties 2304. Finas and penal ties 2305. Finas and penal ties 2307. Total (Lines 2301 through 2303 plus 2398)(Line 23 above) 2308. Summary of remaining write-ins for Line 23 from overflow page 2399. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above) 2309. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above) 2300. XXX 2300. XX		authorized reinsurers \$ unauthorized				
20. Reinsurance in unauthorized and certified (\$)		, .				
21		,				
21. Net adjustments in assets and liabilities due to foreign exchange rates	20.	Reinsurance in unauthorized and certified (\$				
21. Net adjustments in assets and liabilities due to foreign exchange rates		companies				
22. Liability for amounts held under uninsured plans.	21	·				
23. Aggregate write-ins for other liabilities (including \$ 156,250 ourrent)						
156,250			6,290,733		6,290,733	41,079
24. Total liabilities (Lines 1 to 23)	23.	, , , , , , , , , , , , , , , , , , ,				
25. Aggregate write-ins for special surplus funds. XXX XX		current)	156,250		156,250	34,910
25. Aggregate write-ins for special surplus funds. XXX XX	24					
26. Common capital stock XXX XXX <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td></td<>						
27. Preferred capital stock. XXX. XXX. XXX. XXX. 113,515,000 81,015,000	25.					
28. Gross paid in and contributed surplus. XXX XXX XXX 113,515,000 81,015, 29. Surplus notes. XXX	26.	Common capital stock	XXX	XXX		
29. Surplus notes	27.	Preferred capital stock	XXX	XXX		
29. Surplus notes	28	Gross paid in and contributed surplus	XXX	XXX	113 515 000	81 015 000
30. Aggregate write-ins for other-than-special surplus funds						
31. Unassigned funds (surplus)	29.					
32. Less treasury stock, at cost: 32.1	30.					
32. Less treasury stock, at cost: 32.1	31.	Unassigned funds (surplus)	XXX	XXX	57,300,243	(7,738,775)
32.1	32					
\$	02.	-				
32.2		·				
\$		\$	XXX	XXX		
33. Total capital and surplus (Lines 25 to 31 minus Line 32) XXX XXX XXX 73,276, 34. Total liabilities, capital and surplus (Lines 24 and 33) XXX XXX XXX 369,403,436 242,216, 242,216		32.2 shares preferred (value included in Line 27				
33. Total capital and surplus (Lines 25 to 31 minus Line 32) XXX XXX XXX 73,276, 34. Total liabilities, capital and surplus (Lines 24 and 33) XXX XXX XXX 369,403,436 242,216, 242,216		\$	XXX	XXX		
34. Total liabilities, capital and surplus (Lines 24 and 33) XXX XXX 369,403,436 242,216, DETAILS OF WRITE-INS 2301. Amounts due to government agencies 34, 2302. Fines and penal ties 156,250 156,250 2303. Summary of remaining write-ins for Line 23 from overflow page 2398. Summary of remaining write-ins for Line 23 above) 156,250 156,250 34, 2501. XXX XXX XXX XXX XXX 2502. XXX XXX XXX XXX XXX 2503. XXX XXX XXX XXX XXX 2598. Summary of remaining write-ins for Line 25 from overflow page XXX XXX XXX 2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above) XXX XXX XXX 3001. XXX XXX XXX 3002. XXX XXX XXX 3003. XXX XXX XXX	20					
DETAILS OF WRITE-INS 2301. Amounts due to government agencies 34, 2302. Fines and penalties 156,250 2303. 156,250 2398. Summary of remaining write-ins for Line 23 from overflow page 2399. Totals (Lines 2301 through 2303 plus 2398)(Line 23 above) 2501. XXX 2502. XXX 2503. XXX 2504. XXX 2598. Summary of remaining write-ins for Line 25 from overflow page XXX 2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above) XXX 3001. XXX 3002. XXX 3003. XXX	33.					
2301. Amounts due to government agencies 34, 2302. Fines and penalties 156,250 2303. 156,250 2398. Summary of remaining write-ins for Line 23 from overflow page 156,250 2399. Totals (Lines 2301 through 2303 plus 2398)(Line 23 above) 156,250 2501. XXX 2502. XXX 2503. XXX 2598. Summary of remaining write-ins for Line 25 from overflow page XXX 2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above) XXX 3001. XXX 3002. XXX 3003. XXX	34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	369,403,436	242,216,795
2302. Fines and penalities 156,250 156,250 2303. 2398. Summary of remaining write-ins for Line 23 from overflow page 2399. Totals (Lines 2301 through 2303 plus 2398)(Line 23 above) 156,250 34, 2501. XXX XXX XXX 2502. XXX XXX XXX 2593. XXX XXX XXX 2598. Summary of remaining write-ins for Line 25 from overflow page XXX XXX 2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above) XXX XXX 3001. XXX XXX 3002. XXX XXX 3003. XXX XXX		DETAILS OF WRITE-INS				
2302. Fines and penalities 156,250 156,250 2303. 2398. Summary of remaining write-ins for Line 23 from overflow page 2399. Totals (Lines 2301 through 2303 plus 2398)(Line 23 above) 156,250 34, 2501. XXX XXX XXX 2502. XXX XXX XXX 2593. XXX XXX XXX 2598. Summary of remaining write-ins for Line 25 from overflow page XXX XXX 2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above) XXX XXX 3001. XXX XXX 3002. XXX XXX 3003. XXX XXX	2301	Amounts due to government agencies				34 910
2303. 2398. Summary of remaining write-ins for Line 23 from overflow page						,
2398. Summary of remaining write-ins for Line 23 from overflow page 156,250 156,250 34, 2399. Totals (Lines 2301 through 2303 plus 2398)(Line 23 above) 156,250 34, 2501. XXX XXX XXX 2502. XXX XXX XXX 2503. XXX XXX XXX 2598. Summary of remaining write-ins for Line 25 from overflow page XXX XXX XXX 2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above) XXX XXX XXX 3001. XXX XXX XXX 3002. XXX XXX XXX 3003. XXX XXX XXX		·				
2399. Totals (Lines 2301 through 2303 plus 2398)(Line 23 above) 156,250 156,250 34, 2501	2303.					
2399. Totals (Lines 2301 through 2303 plus 2398)(Line 23 above) 156,250 156,250 34, 2501	2398.	Summary of remaining write-ins for Line 23 from overflow page				
2501.						34,910
2502.			,	100/	,	,
2503.						
2598. Summary of remaining write-ins for Line 25 from overflow page .XXX .XXX 2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above) .XXX .XXX 3001	2502.		XXX	XXX		
2598. Summary of remaining write-ins for Line 25 from overflow page .XXX .XXX 2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above) .XXX .XXX 3001	2503.		XXX	XXX		
2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above) XXX XXX 3001. XXX XXX 3002. XXX XXX 3003. XXX XXX						
3001.						
3002XXXXXX						
3003	3001.		XXX	XXX		
3003	3002.		XXX	XXX		
3098. Summary of remaining write-ins for Line 30 from overflow page	3098.	Summary of remaining write-ins for Line 30 from overflow page	XXX	XXX		
3099. Totals (Lines 3001 through 3003 plus 3098)(Line 30 above) XXX XXX	3099.	Totals (Lines 3001 through 3003 plus 3098)(Line 30 above)	XXX	XXX		

STATEMENT OF REVENUE AND EXPENSES

				5: 1/
		Currei 1	nt Year 2	Prior Year 3
		Uncovered	Total	Total
1.	Member Months	XXX	2,397,594	1,129,967
2.	Net premium income (including \$ non-health premium income)	XXX	1,512,884,014	633,982,781
3.	Change in unearned premium reserves and reserve for rate credits			
4.	Fee-for-service (net of \$ medical expenses)			
5.	Risk revenue			
6.	Aggregate write-ins for other health care related revenues	XXX		
7.	Aggregate write-ins for other non-health revenues	XXX		
8.	Total revenues (Lines 2 to 7)	XXX	1,512,884,014	633,982,781
	Hospital and Medical:			
9.	Hospital/medical benefits		937,889,746	378,582,272
10.	Other professional services		13.753.743	5,609,586
11.	Outside referrals			52 588 799
			, ,	53,743,595
12.	Emergency room and out-of-area			
13.	Prescription drugs			95,685,273
14.	Aggregate write-ins for other hospital and medical			
15.	Incentive pool, withhold adjustments and bonus amounts		10,318,759	4,563,129
16.	Subtotal (Lines 9 to 15)		1,305,914,804	590,772,654
	Less:			
17.	Net reinsurance recoveries			
18.	Total hospital and medical (Lines 16 minus 17)		1 305 914 804	590 772 654
19.	Non-health claims (net)			
	` '			
20.	Claims adjustment expenses, including \$42,739,399 cost containment expenses			
21.	General administrative expenses		82,054,718	31,769,663
22.	Increase in reserves for life and accident and health contracts (including \$			
	increase in reserves for life only)			
23.	Total underwriting deductions (Lines 18 through 22)		1,434,962,688	643,326,456
24.	Net underwriting gain or (loss) (Lines 8 minus 23)			(9,343,675)
25.	Net investment income earned (Exhibit of Net Investment Income, Line 17)			` ' ' '
26.	Net realized capital gains (losses) less capital gains tax of \$			
27.	Net investment gains (losses) (Lines 25 plus 26)		14,815,590	3,918,081
28.	Net gain or (loss) from agents' or premium balances charged off [(amount recovered			
	\$) (amount charged off \$			
29.	Aggregate write-ins for other income or expenses		35,750	(192,000)
30.	Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus			
	27 plus 28 plus 29)	XXX	92,772,666	(5,617,594)
31.	Federal and foreign income taxes incurred	XXX	19,005,373	580,916
32.	Net income (loss) (Lines 30 minus 31)	XXX	73,767,293	(6,198,510)
	DETAILS OF WRITE-INS			
0601.	DETAILS OF WAITE-ING	VVV		
0602.				
0603				
0698.	Summary of remaining write-ins for Line 6 from overflow page			
0699.	Totals (Lines 0601 through 0603 plus 0698)(Line 6 above)	XXX		
0701.		XXX		
0702.		XXX		
0703		XXX		
0798.	Summary of remaining write-ins for Line 7 from overflow page	XXX		
0799.	Totals (Lines 0701 through 0703 plus 0798)(Line 7 above)	XXX		
1401.				
1402.				
1403.				
1498.	Summary of remaining write-ins for Line 14 from overflow page			
1499.	Totals (Lines 1401 through 1403 plus 1498)(Line 14 above)			
2901.	Fines and penalties		35 750	(192,000)
			, .	(192,000)
2902.				
2903				
2998.	Summary of remaining write-ins for Line 29 from overflow page			
2999.	Totals (Lines 2901 through 2903 plus 2998)(Line 29 above)		35,750	(192,000)

STATEMENT OF REVENUE AND EXPENSES (Continued)

		1	2
		Current Year	Prior Year
	CAPITAL AND SURPLUS ACCOUNT		
33.	Capital and surplus prior reporting year	73,276,225	1,013,976
34.	Net income or (loss) from Line 32	73,767,293	(6,198,510)
35.	Change in valuation basis of aggregate policy and claim reserves		
36.	Change in net unrealized capital gains (losses) less capital gains tax of \$		
37.	Change in net unrealized foreign exchange capital gain or (loss)		
38.	Change in net deferred income tax	4,383,055	
39.	Change in nonadmitted assets	(13,111,330)	(1,539,241)
40	Change in unauthorized and certified reinsurance		
41.	Change in treasury stock		
42.	Change in surplus notes		
43.	Cumulative effect of changes in accounting principles		
44.	Capital Changes:		
	44.1 Paid in		
	44.2 Transferred from surplus (Stock Dividend)		
	44.3 Transferred to surplus		
45	Surplus adjustments:		
45.	45.1 Paid in	32 500 000	80 000 000
	45.2 Transferred to capital (Stock Dividend)		
	45.3 Transferred from capital		
46			
46.	Dividends to stockholders		
47.	Aggregate write-ins for gains or (losses) in surplus		72,262,249
48.		170,815,243	73,276,225
49.	Capital and surplus end of reporting period (Line 33 plus 48)	170,615,245	13,210,223
	DETAILS OF WRITE-INS		
4701.			
4702.		-	
4703.			
4798.	Summary of remaining write-ins for Line 47 from overflow page		
4799.	Totals (Lines 4701 through 4703 plus 4798)(Line 47 above)		

CASH FLOW

		1	2
		Current Year	Prior Year
	Cash from Operations		
1.	Premiums collected net of reinsurance		
2.	Net investment income		2,994,662
3.	Miscellaneous income		
4.	Total (Lines 1 through 3)		607,202,189
5.	Benefit and loss related payments		432,883,291
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
7.	Commissions, expenses paid and aggregate write-ins for deductions		48,663,788
8.	Dividends paid to policyholders		
9.	Federal and foreign income taxes paid (recovered) net of \$ tax on capital gains (losses)	11,270,000	290,000
10.	Total (Lines 5 through 9)	1,441,464,578	481,837,079
11.	Net cash from operations (Line 4 minus Line 10)	30,633,393	125,365,110
	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:		
	12.1 Bonds		
	12.2 Stocks		
	12.3 Mortgage loans		
	12.4 Real estate		
	12.5 Other invested assets		
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		
	12.7 Miscellaneous proceeds		
	12.8 Total investment proceeds (Lines 12.1 to 12.7)		
13.	Cost of investments acquired (long-term only):	2,230,002	
13.	13.1 Bonds	92 962 162	
	13.2 Stocks		
	13.3 Mortgage loans		
	13.4 Real estate		
	13.5 Other invested assets		
	13.6 Miscellaneous applications		
	13.7 Total investments acquired (Lines 13.1 to 13.6)	83,862,162	
14.	Net increase/(decrease) in contract loans and premium notes		
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(81,611,310)	
	Cash from Financing and Miscellaneous Sources		
16.	Cash provided (applied):		
	16.1 Surplus notes, capital notes		
	16.2 Capital and paid in surplus, less treasury stock	32,500,000	80,000,000
	16.3 Borrowed funds		
	16.4 Net deposits on deposit-type contracts and other insurance liabilities		
	16.5 Dividends to stockholders		
	16.6 Other cash provided (applied)	(753,644)	4,491,703
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	, , ,	84,491,703
	······································	2,712,000	,,
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	(19,231,561)	209,856,813
19.	Cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	(10,201,001)	250,500,010
13.	19.1 Beginning of year	210,870,517	1,013,704
			, ,
	19.2 End of year (Line 18 plus Line 19.1)	191,638,956	210,870,517

Note: Supplemental disclosures of cash flow information for non-cash transactions:		

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

_				TE I OIO			<u> </u>		OI DO			11	12	10	14
		1	Compre (Hospital &		4	5	6	7	8	9	10	11	12	13	14
			2	3				Federal							
		Total	Individual	Group	Medicare Supplement	Vision Only	Dental Only	Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
	Net premium income	1,512,884,014	42,457,050							1,470,426,964					
2.	Change in unearned premium reserves and reserve for rate credit														
3.	Fee-for-service (net of \$														
	medical expenses)														XXX
	Risk revenue														XXX
6.	Aggregate write-ins for other non-health care related revenues		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
7.	Total revenues (Lines 1 to 6)	1.512.884.014	42.457.050							1.470.426.964					
8.	Hospital/medical benefits	937,889,746	21,036,660							916,853,086					XXX
9.	Other professional services	13,753,743	764,412							12,989,331					XXX
	Outside referrals	31,651,081	1,048,873							30,602,208					XXX
	Emergency room and out-of-area	110,731,305	5, 135, 423							105,595,882					XXX
12.	Prescription drugs	201,570,170	7,807,856							193,762,314					XXX
13.	Aggregate write-ins for other hospital and medical	201,070,170								100,702,014					XXX
	Incentive pool, withhold adjustments and bonus														
14.	amounts	10,318,759	888,810							9.429.949					xxx
15.	Subtotal (Lines 8 to 14)	1,305,914,804	36,682,034							1,269,232,770					XXX
16.	Net reinsurance recoveries	1,000,011,001								1,200,202,770					XXX
	Total medical and hospital (Lines 15 minus 16)	1,305,914,804	36,682,034							1,269,232,770					XXX
	Non-health claims (net)	1,000,314,004	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXXXX	XXX	XXX	XXX	XXX	
	Claims adjustment expenses including														
19.	\$ 42,739,399 cost containment expenses	46.993.166	1,710,347							45.282.819					
20	General administrative expenses	82,054,718	2.940.604			•••••									
	Increase in reserves for accident and health	02,004,710	2,940,004							/9,114,114					
21.	contracts														XXX
22.	Increase in reserves for life contracts		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	700
23.	Total underwriting deductions (Lines 17 to 22)	1,434,962,688	41,332,985							1,393,629,703				700	
	Net underwriting gain or (loss) (Line 7 minus Line	1, 101,002,000								1,000,020,700 .					
24.	23)	77,921,326	1, 124, 065							76,797,261					
0504	DETAILS OF WRITE-INS														XXX
0501.															
0502.		• • • • • • • • • • • • • • • • • • • •													XXX
0503. 0598.	Summary of remaining write-ins for Line 5 from overflow page														XXX
0599.	Totals (Lines 0501 through 0503 plus 0598) (Line 5 above)						•••••		•••••						XXX
0601.	above)		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	^^^
0602.			XXX		XXX	XXX	XXX	XXX		XXX	XXX	XXX	XXX	XXX	
0603.			XXX	XXX	XXX			XXX	XXX	XXX	XXX	XXX		XXX	
0698.	Summary of remaining write-ins for Line 6 from														
0699.	overflow page		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
	above)		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
1301.															XXX
1302.														.	XXX
1303.															XXX
1398.	Summary of remaining write-ins for Line 13 from overflow page														xxx
1399.	Totals (Lines 1301 through 1303 plus 1398) (Line 13 above)														XXX

m

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Molina Healthcare of Iowa, Inc.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMILIMS

PARI 1 - PREMIUMS	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
Comprehensive (hospital and medical) individual				42,457,050
Comprehensive (hospital and medical) group				
3. Medicare Supplement				
4. Vision only				
5. Dental only				
6. Federal Employees Health Benefits Plan				
7. Title XVIII - Medicare				
8. Title XIX - Medicaid	1,470,426,964			1,470,426,964
9. Credit A&H				
10. Disability Income				
11. Long-Term Care				
12. Other health				
13. Health subtotal (Lines 1 through 12)	1,512,884,014			1,512,884,014
14. Life				
15. Property/casualty				
16. Totals (Lines 13 to 15)	1,512,884,014			1,512,884,014

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

		1	Compreh (Hospital &		4	5	6	7	8	9	10	11	12	13	14
		Total	2 Individual	3 Group	Medicare Supplement	Vision Only	Dental Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
1.	Payments during the year:														
	1.1 Direct	1,322,476,528	35,879,336							1,286,597,192					
	1.2 Reinsurance assumed														
	1.3 Reinsurance ceded														
	1.4 Net	1,322,476,528	35,879,336							1,286,597,192					
2.	Paid medical incentive pools and														
	bonuses	3,491,600								3,491,600					
3.	Claim liability December 31, current year from Part 2A:														
	3.1 Direct	145,402,412	2,954,029							142,448,383					
	3.2 Reinsurance assumed														
	3.3 Reinsurance ceded														
	3.4 Net	145,402,412	2,954,029							142,448,383					
4.	Claim reserve December 31, current year from Part 2D: 4.1 Direct														
	4.3 Reinsurance ceded														
	4.4 Net														
_															
	Accrued medical incentive pools and bonuses, current year	11,387,753	, ,							10,275,891					
	Net health care receivables (a)	18,232,705	054,011							17,576,094					
8.	Claim liability December 31, prior year from Part 2A:	154.050.190	2 .386 .130							151.664.060					
	8.2 Reinsurance assumed														
	8.3 Reinsurance ceded														
	8.4 Net	154.050.190	2.386.130							151,664,060					
9.	Claim reserve December 31, prior year from Part 2D: 9.1 Direct	10 1,000, 100	2,000,100							101,001,000					
	9.2 Reinsurance assumed														
	9.3 Reinsurance ceded														
	9.4 Net								• • • • • • • • • • • • • • • • • • • •			• • • • • • • • • • • • • • • • • • • •			
10.	Accrued medical incentive pools and bonuses, prior year	4,560,594	223,052							4,337,542					
11.	Amounts recoverable from reinsurers December 31, prior year														
12.	Incurred Benefits:														
	12.1 Direct	1,295,596,045	35,793,224			L		[1,259,802,821					
	12.2 Reinsurance assumed	1,200,000,040								,200,002,021					
	12.3 Reinsurance ceded								•••••			•••••			
	12.4 Net	1,295,596,045	35,793,224			1				1,259,802,821					
40		1,290,090,045	33,183,224							1,208,002,821					
13.	Incurred medical incentive pools and bonuses	10,318,759	888,810							9,429,949					

⁽a) Excludes \$ loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

	1	Compre	hensive	PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR sive 4 5 6 7 8 9 10							11	12	13	14
	'	(Hospital &		7					3	10		12	13	'7
		2	3				Federal							
				Medicare			Employees Health	Title XVIII	Title XIX		Disability	Long-Term		Other
	Total	Individual	Group	Supplement	Vision Only	Dental Only	Benefits Plan	Medicare	Medicaid	Credit A&H	Income	Care	Other Health	Non-Health
Reported in Process of Adjustment:														
1.1 Direct	10,818,787	465,228							10,353,559					
1.2 Reinsurance assumed														
1.3 Reinsurance ceded														
1.4 Net	10,818,787	465,228							10,353,559					
		,							, ,					
Incurred but Unreported:														
2.1 Direct	134 583 625	2 488 801							132 094 824					
2.2 Reinsurance assumed														
2.3 Reinsurance ceded														
2.4 Net	134,583,625	2,488,801							132,094,824					
Amounts Withheld from Paid Claims and Capitations:														
3.1 Direct														
3.2 Reinsurance assumed														
3.3 Reinsurance ceded														
3.4 Net														
4. TOTALS:														
4.1 Direct	145,402,412	2,954,029							142,448,383					
4.2 Reinsurance assumed														
4.3 Reinsurance ceded														
4.4 Net	145,402,412	2,954,029							142,448,383					

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRI				and Claim Liability	5	6
	Claims Paid D	ouring the Year	December 31	of Current Year		Estimated Claim
			3	7		Reserve and Claim
	On Claims Incurred		On Claims Unpaid		Claims Incurred	Liability
	Prior to January 1	On Claims Incurred	December 31 of	On Claims Incurred	In Prior Years	December 31 of
Line of Business	of Current Year	During the Year	Prior Year	During the Year	(Columns 1 + 3)	Prior Year
Comprehensive (hospital and medical) individual	1,652,057	34,227,279	12,804	2,941,225	1,664,861	2,386,130
Comprehensive (hospital and medical) group						
3. Medicare Supplement						
4. Vision Only						
5. Dental Only						
6. Federal Employees Health Benefits Plan						
7. Title XVIII - Medicare						
8 Title XIX - Medicaid	134 , 156 , 611	1,152,440,581	159,914	142,288,470	134,316,525	151,664,060
9. Credit A&H						
10. Disability Income						
11. Long-Term Care						
12. Other health						
13. Health subtotal (Lines 1 to 12)						
14. Health care receivables (a)	7,812	18,934,445		11,870	7,812	721,421
15. Other non-health						
16. Medical incentive pools and bonus amounts					1,409,144	
17. Totals (Lines 13 - 14 + 15 + 16)	137, 175, 455	1,169,850,416	207,263	156,571,033	137,382,718	157,889,363

⁽a) Excludes \$ loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

	Coolon A Tala Hould Cambrotichoro (Hoopital a III	•	Cu	mulative Net Amounts F	Paid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2020	2021	2022	2023	2024
1.	Prior					
2.	2020					
3.	2021	XXX				
4.	2022	XXX	XXX			
5.	2023	XXX	XXX	XXX	8,150	9,802
6.	2024	XXX	XXX	XXX	XXX	34,227

Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

	Sum of Cumu	lative Net Amount Paid and Cla Oเ	im Liability, Claim Resoutstanding at End of Ye	erve and Medical Incent ear	ive Pool and Bonuses
	1	2	3	4	5
Year in Which Losses Were Incurred	2020	2021	2022	2023	2024
1. Prior					
2. 2020					
3. 2021	XXX				
4. 2022	XXX	xxx			
5. 2023	XXX	XXX	XXX	10,759	9,818
6. 2024	XXX	XXX	XXX	XXX	38,277

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment Expense Payments	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2020										
2.	2021										
3	2022										
4	2023	12.310	9.802	501	5.1	10.303	83.7	16		10.319	83.8
5.	2024	42,457	34,227	1,710	5.0	35,937	84.6	4,050	17	40,004	94.2

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Title XIX

			Cı	umulative Net Amounts F	Paid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2020	2021	2022	2023	2024
1.	Prior					
2.	2020					
3.	2021	XXX				
4.	2022	XXX	XXX			
5.	2023	XXX	XXX	XXX	424,733	560,264
6.	2024	XXX	XXX	XXX	XXX	1,154,558

Section B - Incurred Health Claims - Title XIX

	Sum of Cumulative Ne	et Amount Paid and Cl	aim Liability, Claim Rese Outstanding at End of Ye	erve and Medical Incent ar	ive Pool and Bonuses	
	1 2 3 4					
Year in Which Losses Were Incurred	2020	2021	2022	2023	2024	
1. Prior						
2. 2020						
3. 2021	XXX					
4. 2022	XXX	XXX				
5. 2023	XXX	XXX	xxx	580,735	560,455	
6. 2024	XXX	XXX	XXX	XXX	1,307,091	

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XIX

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2020										
2.	2021										
3	2022										
4	2023		560.264	20.284	3.6	580.548	93.4	191	3	580.742	93.4
5.	2024	1,470,427	1,154,558	45,283	3.9	1,199,841	81.6	152,533	923	1,353,297	92.0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Grand Total

			Cı	umulative Net Amounts F	Paid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2020	2021	2022	2023	2024
1.	Prior					
2.	2020					
3.	2021	XXX				
4	2022	XXX	XXX			
5	2023	XXX	XXX	XXX	432 .883	570.066
6.	2024	XXX	XXX	XXX	XXX	1,188,785

Section B - Incurred Health Claims - Grand Total

	Sum of Cumulative Ne	et Amount Paid and Cl	aim Liability, Claim Rese Outstanding at End of Ye	erve and Medical Incent ar	ve Pool and Bonuses	
	1 2 3 4					
Year in Which Losses Were Incurred	2020	2021	2022	2023	2024	
1. Prior						
2. 2020						
3. 2021	XXX					
4. 2022	XXX	XXX				
5. 2023	XXX	XXX	xxx	591,494	570,273	
6. 2024	XXX	XXX	XXX	XXX	1,345,368	

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)	.	Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2020										
2.	2021										
3.	2022										
4.	2023	633,983	570.066	20.785	3.6	590.851	93.2	207	3	591.061	93.2
5.	2024	1,512,884	1,188,785	46,993	4.0	1,235,778	81.7	156,583	940	1,393,301	92.1

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

					GATE RESERVI	E FOR ACCIDE	NT AND HEAL	TH CONTRACT	SONLY					
		1	Compre (Hospital 8	hensive & Medical)	4	5	6	7	8	9	10	11	12	13
		Total	2 Individual	3 Group	Medicare Supplement	Vision Only	Dental Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other
1.	Unearned premium reserves													
2.	Additional policy reserves (a)													
3.														
4.	Reserve for rate credits or experience rating refunds													
	(including \$ for investment income)													
5.	Aggregate write-ins for other policy reserves													
6.	Totals (gross)													
7.	Reinsurance ceded													
8.	Totals (Net)(Page 3, Line 4)													
9.	Present value of amounts not yet due on claims													
10.	Reserve for future contingent benefits													
11.	Aggregate write-ins for other claim reserves													
12.	Totals (gross)						\							
13.	Reinsurance ceded													
14.	Totals (Net)(Page 3, Line 7)													
	DETAILS OF WRITE-INS													
0501.														
0502.														
0503.														
0598.	Summary of remaining write-ins for Line 5 from overflow page													
0599.	Totals (Lines 0501 through 0503 plus 0598) (Line 5 above)													
1101.														
1102.														
1103.														
1198.	Summary of remaining write-ins for Line 11 from overflow page													
1199.	Totals (Lines 1101 through 1103 plus 1198) (Line 11 above)													

(a) Includes \$ premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES

		Claim Adjustme	nt Expenses	3	4	5
		Cost Containment Expenses	Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
1.	Rent (\$ for occupancy of					
	own building)			426,903		426,903
2.	Salary, wages and other benefits	28,996,585	247,977	32,100,928		61,345,490
3.	Commissions (less \$					
	ceded plus \$ assumed)					
4.	Legal fees and expenses			1,189,197		1, 189, 197
5.	Certifications and accreditation fees	31,769		1,707		33,476
6.	Auditing, actuarial and other consulting services	423,578	663,299	3,808,240		4,895,117
7.	Traveling expenses	545,938	283	335,910		882,131
8.	Marketing and advertising	537,310		1,257,256		1,794,566
9.	Postage, express and telephone	317,761	169	892,713		1,210,643
10.	Printing and office supplies	25,815	4	1,087,462		1,113,281
11.	Occupancy, depreciation and amortization			2,419,071		2,419,071
12.	Equipment	101		156,296		156,397
13.	Cost or depreciation of EDP equipment and software	1,124,308	8 .	10,751,984		11,876,300
14.	Outsourced services including EDP, claims, and other services	8 766 039	3 322 738	6 658 000		18 746 777
15.	Boards, bureaus and association fees			91,231		
16.	Insurance, except on real estate			264,706		
17.	Collection and bank service charges			·		•
18.	Group service and administration fees					
19.	Reimbursements by uninsured plans					
20.	Reimbursements from fiscal intermediaries					
21.	Real estate expenses					
22.	•					
23.	Taxes, licenses and fees:					
20.	23.1 State and local insurance taxes					
	23.2 State premium taxes			14 264 528		14 264 528
	23.3 Regulatory authority licenses and fees					
	23.4 Payroll taxes					
	23.5 Other (excluding federal income and real estate taxes)					
24.	Investment expenses not included elsewhere					21,28
25.	Aggregate write-ins for expenses			3,910,478	,	3,910,478
26.	Total expenses incurred (Lines 1 to 25)	42 739 399	4 253 767		33 261	
27.				19,434,012		
28.				3,003,391		
29.	Amounts receivable relating to uninsured plans,					,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
30.	Amounts receivable relating to uninsured plans, current year					
31.	Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	42,766,592	4,305,753	65,624,097	33,261	112,729,703
	DETAILS OF WRITE-INS					
2501.	Borrowing costs			3,910,350		3,910,350
2502.	Other administrative expenses			128		128
2503.						
2598.	Summary of remaining write-ins for Line 25 from overflow page					
	Totals (Lines 2501 through 2503 plus 2598)(Line 25 above) des management fees of \$	600		3,910,478		3,910,478

EXHIBIT OF NET INVESTMENT INCOME

			1	2
				Earned During Year
1.	U.S. government bonds	` '		
1.1	Bonds exempt from U.S. tax			
1.2				2,468,580
1.3	Bonds of affiliates			
2.1	Preferred stocks (unaffiliated)	. ,		
2.11	Preferred stocks of affiliates	. ,		
2.2				
2.21	Common stocks of affiliates			
3.	Mortgage loans			
4.	Real estate	` '		
5	Contract Loans			
6	Cash, cash equivalents and short-term investments	(e)	. 12,685,471	12,380,271
7	Derivative instruments	` '		
8.	Other invested assets			
9.	Aggregate write-ins for investment income			
10.	Total gross investment income		14,381,141	14,848,851
11.	Investment expenses			
12.	Investment taxes, licenses and fees, excluding federal income taxes			(g)
13.	Interest expense			
14.	Depreciation on real estate and other invested assets			()
15.	Aggregate write-ins for deductions from investment income			
16.	Total deductions (Lines 11 through 15)			
17.	Net investment income (Line 10 minus Line 16)			14,815,590
	DETAILS OF WRITE-INS			
0901.				
0902.				
0903.				
0998.	Summary of remaining write-ins for Line 9 from overflow page			
0999.	Totals (Lines 0901 through 0903 plus 0998) (Line 9, above)			
1501.				
1502.				
1503.				
1598.	Summary of remaining write-ins for Line 15 from overflow page			
1599.	Totals (Lines 1501 through 1503 plus 1598) (Line 15, above)			
(a) Inclu	des \$232,515 accrual of discount less \$16,248 amortization of premium and less \$301,6	98 paid fo	r accrued into	erest on purchases.
. ,		•		•
(b) Inclu	des \$ accrual of discount less \$ amortization of premium and less \$	paid fo	r accrued div	idends on purchases.
(c) Inclu	des \$ accrual of discount less \$ amortization of premium and less \$	paid fo	r accrued into	erest on purchases.
(d) Inclu	des \$ for company's occupancy of its own buildings; and excludes \$ interest on en	cumbrance	es.	
(e) Inclu	des \$ accrual of discount less \$ amortization of premium and less \$	paid fo	r accrued into	erest on purchases.
(f) Includ	des \$ accrual of discount less \$ amortization of premium.			
	des \$33,261 investment expenses and \$ investment taxes, licenses and fees, excluding for regated and Separate Accounts.	ederal incor	me taxes, atti	ributable to

EXHIBIT OF CAPITAL GAINS (LOSSES)

(h) Includes \$ interest on surplus notes and \$ interest on capital notes.

(i) Includes \$ depreciation on real estate and \$ depreciation on other invested assets.

	EVUIDII	OF CAPI	IAL GAIN	3 (LU33E	.3)	
		1	2	3	4	5
				Total Realized Capital	Change in	Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity	Adjustments	(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds					
1.1	Bonds exempt from U.S. tax					
1.2	Other bonds (unaffiliated)					
1.3	Bonds of affiliates					
2.1	Preferred stocks (unaffiliated)					
2.11	Preferred stocks of affiliates					
2.2	Common stocks (unaffiliated)					
2.21	Common stocks of affiliates					
3.	Mortgage loans					
4.	Real estate			<u></u>		
5.	Contract loans					
6.	Cash, cash equivalents and short-term investmen		. 			
7.	Derivative instruments					
8.	Other invested assets					
9.	Aggregate write-ins for capital gains (losses)					
10.	Total capital gains (losses)					
	DETAILS OF WRITE-INS					
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from overflow page					
0999.	Totals (Lines 0901 through 0903 plus 0998) (Line 9, above)					

EXHIBIT OF NON-ADMITTED ASSETS

	EXHIBIT OF NON-ADMITTE	DASSEIS		
		1	2	3 Change in Total
		Current Year Total Nonadmitted Assets	Prior Year Total Nonadmitted Assets	Nonadmitted Assets (Col. 2 - Col. 1)
1	Panda (Sahadula D)	Nonaumilled Assets	Nonadmilled Assets	(Coi. 2 - Coi. 1)
	Bonds (Schedule D) Stocks (Schedule D):			
۷.	2.1 Preferred stocks			
	2.2 Common stocks			
•				
3.	Mortgage loans on real estate (Schedule B):			
	3.1 First liens			
	3.2 Other than first liens			
4.	Real estate (Schedule A):			
	4.1 Properties occupied by the company			
	4.2 Properties held for the production of income			
_	4.3 Properties held for sale			
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)			
6.	Contract loans			
7.	Derivatives (Schedule DB)			
8.	Other invested assets (Schedule BA)			
9.	Receivables for securities			
10.	Securities lending reinvested collateral assets (Schedule DL)			
11.	Aggregate write-ins for invested assets			
12.	Subtotals, cash and invested assets (Lines 1 to 11)			
13.	Title plants (for Title insurers only)			
14.	Investment income due and accrued			
15.	Premiums and considerations:			
	15.1 Uncollected premiums and agents' balances in the course of collection			
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due			
	15.3 Accrued retrospective premiums and contracts subject to redetermination			
16.	Reinsurance:			
	16.1 Amounts recoverable from reinsurers			
	16.2 Funds held by or deposited with reinsured companies			
	16.3 Other amounts receivable under reinsurance contracts			
17	Amounts receivable relating to uninsured plans			
	Current federal and foreign income tax recoverable and interest thereon			
	Net deferred tax asset			
19.	Guaranty funds receivable or on deposit			
20.	Electronic data processing equipment and software			
	Furniture and equipment, including health care delivery assets			
21.	Net adjustment in assets and liabilities due to foreign exchange rates			
22.	Receivable from parent, subsidiaries and affiliates			
23.	Health care and other amounts receivable			
24.				
25.	Aggregate write-ins for other-than-invested assets	947,390	1, 100,021	200,920
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	14,650,571	1,539,241	(13,111,330)
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			
28.	Total (Lines 26 and 27)	14,650,571	1,539,241	(13,111,330)
	DETAILS OF WRITE-INS			
1101.				
1102.				
1103.				
1198.	Summary of remaining write-ins for Line 11 from overflow page			
1199.	Totals (Lines 1101 through 1103 plus 1198)(Line 11 above)			
2501.	Prepaids, deposits, and other assets	947 398	1 183 321	235 923
2501.	Treparus, deposits, and other assets			
2502.				
2598.	Summary of remaining write-ins for Line 25 from overflow page			
		947,398		
2599.	Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)	341,398	1, 100, 321	200,823

17

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

		Total Members at End of						
Source of Enrollment	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	Current Year Member Months		
Health Maintenance Organizations		199,596	201,480	200,665	199,293	2,397,594		
Provider Service Organizations								
Preferred Provider Organizations								
4. Point of Service								
5. Indemnity Only								
Aggregate write-ins for other lines of business								
7. Total	170,929	199,596	201,480	200,665	199,293	2,397,594		
DETAILS OF WRITE-INS								
0601.								
0602.								
0603.								
0698. Summary of remaining write-ins for Line 6 from overflow page								
0699. Totals (Lines 0601 through 0603 plus 0698) (Line 6 above)								

NOTE 1 Summary of Significant Accounting Policies and Going Concern

Organization and Operations

Molina Healthcare of lowa, Inc. (the Plan) was incorporated under the laws of the state of lowa on December 28, 2021. The Plan is a wholly owned subsidiary of Molina Healthcare, Inc. (Molina, or the Parent), a multi-state managed care organization that arranges for the delivery of healthcare services to persons eligible for Medicaid, Medicare, the state insurance marketplaces (the Marketplace), and other government-sponsored health care programs for low-income families and

The Plan is a health maintenance organization (HMO), licensed in the state of lowa, that provides comprehensive health care services to Medicaid enrollees under the contract with the lowa Department of Human Services (HHS). This contract represents the Plan's source of premium income for the years ended December 31, 2024 and 2023.

The Plan contracts with independent physician associations, hospitals and other providers to provide medical services to its members. As an HMO, the Plan is at risk for all covered outpatient and inpatient claims incurred by its beneficiaries.

A. Accounting Practices

The financial statements of the Plan are presented on the basis of accounting practices prescribed or permitted by the lowa Insurance Division (the Department).

The Department recognizes only statutory accounting practices prescribed or permitted by the state of lowa for determining and reporting the financial condition and results of operations of an insurance company, for determining its solvency under the lowa insurance law. The National Association of Insurance Commissioners' Accounting Practices and Procedures Manual (NAIC SAP) has been adopted as a component of prescribed or permitted practices by the state of lowa.

Such prescribed accounting practices have no significant effect on the Plan's statutory basis financial statements for the periods presented.

	SSAP#	F/S Page	F/S Line #	2024	 2023
NET INCOME (1) State basis (Page 4, Line 32, Columns 2 & 3)	xxx	xxx	XXX	\$ 73,767,293	\$ (6,198,510)
(2) State Prescribed Practices that are an increase/(decrease)	from NAIC SA	AP:			
(3) State Permitted Practices that are an increase/(decrease) f	rom NAIC SAF	> :			
(4) NAIC SAP (1-2-3=4)	XXX	XXX	XXX	\$ 73,767,293	\$ (6,198,510)
SURPLUS (5) State basis (Page 3, Line 33, Columns 3 & 4)	xxx	XXX	XXX	\$ 170,815,243	\$ 73,276,225
(6) State Prescribed Practices that are an increase/(decrease)	from NAIC SA	AP:			
(7) State Permitted Practices that are an increase/(decrease) f	rom NAIC SAF	> :			
(8) NAIC SAP (5-6-7=8)	XXX	XXX	XXX	\$ 170,815,243	\$ 73,276,225

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of financial statements in conformity with Statutory Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. It also requires disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

C. Accounting Policy

The Plan applies the following accounting policies:

- (1) Basis for Short-Term Investments: Short-term investments consist primarily of U.S. treasury notes and investments in corporate debt securities with maturity dates of greater than three months but less than one year at the time of acquisition. The basis of short-term investments is the same as for bonds as stated in Note 1C(2).
- (2) Basis for Bonds and Amortization Schedule: Bonds include U.S. government and other debt securities with maturity dates of greater than one year at the time of purchase. Bonds not backed by other loans are principally stated at amortized cost using the scientific method. Bonds with NAIC designations of one or two are stated at amortized cost. Bonds with NAIC designations of three or higher are stated at the lower of amortized cost or fair value. Amortization of bond premium or accretion of discount is computed using the scientific (constant-yield) interest method. Realized capital gains and losses are determined using the specific-identification method and were not significant for the years ended December 31, 2024 and 2023. There were no significant unrealized gains or losses on investments, and the Plan recognized no losses from other-than-temporary impairments for the years ended December 31, 2024 and 2023.
- (3) Investments in common stock: None.
- (4) Investments in preferred stock: None
- (5) Investments in mortgage loans: None.
- (6) Basis for Loan-Backed Securities and Adjustment Methodology: Loan-backed securities are stated at amortized cost or lower of amortized cost or fair value. The Plan's investments in loan-backed securities consist of asset-backed securities, mortgage-backed securities, and commercial mortgage-backed securities. Prepayment assumptions using a prospective approach were generated using a prepayment model. On an ongoing basis, the Plan monitors the rate of prepayment and calibrates the model to reflect actual experience, market factors, and viewpoint.
- (7) Investments in subsidiaries, controlled and affiliated entities (SCA): None.
- (8) Investments in joint ventures, partnerships and limited liability companies: None.
- (9) Investments in derivatives: None.
- (10) Anticipated Investment Income Used in Premium Deficiency Calculation: The Plan anticipates investment income as a factor in the premium deficiency calculation, in accordance with Statement of Statutory Accounting Principles (SSAP) No. 54R, Individual and Group Accident and Health Contracts. The Plan assesses the profitability of its medical care policies, grouped in a manner consistent with how policies are marketed, serviced and measured. If anticipated future costs exceed anticipated future premiums and investment income, a premium deficiency reserve is recognized. Refer to Note 30, "Premium Deficiency Reserves" for further information.

- Management's Policies and Methodologies for Estimating Liabilities for Losses and Loss/Claim Adjustment Expenses for Accident & Health Contracts: Claims unpaid are based on actual historical experience and estimates of medical expenses incurred but not paid (IBNP). The Plan employs its own actuaries to estimate IBNP monthly. The estimation of the IBNP liability requires a significant degree of judgment in applying actuarial methods, determining the appropriate assumptions and considering numerous factors. Of those factors, the Plan considers estimated completion factors and the assumed healthcare cost trend to be the most critical assumptions. Other relevant factors also include, but are not limited to, healthcare service utilization trends, claim inventory levels, changes in membership, product mix, seasonality, benefit changes or changes in Medicaid fee schedules, provider contract changes, prior authorizations and the incidence of catastrophic or pandemic cases. Because of the significant degree of judgment involved in estimation of our IBNP liability, there is considerable variability and uncertainty inherent in such estimates. Each reporting period, the recognized IBNP liability represents the Plan's best estimate of the total amount of unpaid claims incurred as of the balance sheet date using a consistent methodology in estimating the IBNP liability. The Plan believes its current estimates are reasonable and adequate; however, the development of our estimate is a continuous process that is monitored and updated as more complete claims payment information and healthcare cost trend data becomes available. Actual hospital and medical expenses may be less than previously estimated (favorable development) or more than previously estimated (unfavorable development), and any differences could be material. Any adjustments to reflect favorable development would be recognized as an increase to hospital and medical expenses, in the period in which the adjustments are determined. Refer to Note 25, "Change in Incurred
- (12) Changes in the Capitalization Policy and Predefined Thresholds from Prior Period: The Plan has not modified its capitalization policy from the prior period.
- (13) Health Care and Other Amounts Receivable: Health care and other amounts receivable primarily consist of amounts receivable for pharmaceutical rebates and claim overpayments. Pharmaceutical rebates are estimated based upon historical and current utilization of prescription drugs and contract terms. The Plan admits estimated pharmaceutical rebate receivables relating to the three months immediately preceding the reporting date in accordance with SSAP No. 84, Health Care and Government Insured Plan Receivables. Claim overpayment receivables are admitted to the extent they meet the admissibility requirements under NAIC SAP. Income from pharmaceutical rebates and the recovery of claim overpayments is reported as a reduction of hospital and medical expenses in the statutory basis statements of revenue and expenses. Refer to Note 28, "Health Care Receivables" for further information.
- D. Going Concern

The Plan is not aware of any relevant conditions or events that raise substantial doubt about its abilities to continue as a going concern.

NOTE 2 Accounting Changes and Corrections of Errors

There were no accounting changes or corrections of errors during the years ended December 31, 2024 and 2023, respectively.

NOTE 3 Business Combinations and Goodwill

None.

NOTE 4 Discontinued Operations

Nono

NOTE 5 Investments

The following tables summarizes the Plan's investments including gross unrealized gains and losses as of the dates indicated:

	Cost or amortized cost	Unrealized gains	Unrealized losses	Fair value
Exempt money market mutual funds	\$ 390,234			\$ 390,234
Industrial and miscellaneous	68,409,934	230,581	620,556	68,019,959
Open depositories	59,531,661			59,531,661
Other money market mutual funds	131,717,061			131,717,061
Political subdivisions	237,789	1,328		239,117
Special revenue & assessment obligations	13,179,854	20,590	111,516	13,088,928
Totals	\$ 273,466,533	\$ 252,499	\$ 732,072	\$ 272,986,960
		Decembe	er 31, 2023	
	Cost or	Unrealized	Unrealized	
	amortized cost	gains	losses	Fair value
Exempt money market mutual funds	\$ 76,083,539			\$ 76,083,539
Open depositories	(10,528,568)			(10,528,568)
Other money market mutual funds	145,315,546	<u> </u>		145,315,546
Totals	\$ 210,870,517	\$ -	\$ -	\$ 210,870,517

December 31 2024

The amortized cost and fair value of the Plan's investments by contractual maturities, were as follows:

	December 31, 2024						
	Ar	mortized cost		Fair value			
Due in one year or less	\$	5,375,380	\$	5,367,045			
Due after one year through five years		60,097,735		59,919,082			
Due after five years through ten years		11,383,767		11,138,099			
Due after ten years through twenty years		3,913,688		3,878,311			
Due after twenty years		1,057,007		1,045,467			
Totals	\$	81,827,577	\$	81,348,004			

- A. Mortgage Loans, including Mezzanine Real Estate Loans: None.
- B. Debt Restructuring: None.
- C. Reverse Mortgages: None.
- D. Loan-Backed Securities:
 - (1) Prepayment assumptions for mortgage-backed securities, collateralized mortgage obligations and other structure securities were generated using a purchased prepayment model. The prepayment model uses a number of factors to estimate prepayment activity including the time of year (seasonally), current levels of interest rates (refinancing incentive), economic activity (including housing turnover) and term and age of the underlying collateral (burnout, seasoning). On an ongoing basis, the rate of prepayment is monitored and model is calibrated to reflect actual experience, market factors and view point.
 - (2), (3) Recognized other-than-temporary impairment (OTTI) securities: None.
 - (4) All impaired securities (fair value is less than cost or amortized cost) for which an OTTI has not been recognized in earnings as a realized loss (including securities with a recognized OTTI for non-interest related declines when a non-recognized interest related impairment remains):

a) The aggregate amount of unrealized losses:

1. Less than 12 Months \$ 243,056
2. 12 Months or Longer \$ b)The aggregate related fair value of securities with unrealized losses:
1. Less than 12 Months \$ 16,207,850
2. 12 Months or Longer \$ -

- (5) Because the decline in the market values of the securities was not due to the credit quality of the issuers, and because the Plan does not intend to sell nor does it expect to be required to sell these securities before a recovery in their cost basis, the Plan does not consider the securities to be other-than-temporarily impaired at December 31, 2024.
- E. Dollar Repurchase Agreements and/or Securities Lending Transactions: None.
- F. Repurchase Agreements Transactions Accounted for as Secured Borrowing: None.
- G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing: None.
- H. Repurchase Agreements Transactions Accounted for as a Sale: None.
- I. Reverse Repurchase Agreements Transactions Accounted for as a Sale: None.
- J. Real Estate: None.
- K. Low Income Housing tax Credits: None.
- L. Restricted Assets: None.
 - Detail of Assets Pledged as Collateral Not Captured in Other Categories (Contracts That Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate): None.
 - 3. Detail of Other Restricted Assets (Contracts That Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate):
 - 4. Collateral Received and Reflected as Assets Within the Reporting Entity's Financial Statements: None.
- M. Working Capital Finance Investments: None.
- N. Offsetting and Netting of Assets and Liabilities: None.
- O 5GI Securities: None
- P. Short Sales: None.
- Q. Prepayment Penalty and Acceleration Fees: None.
- R. Reporting Entity's Share of Cash Pool by Asset Type: None.
- S. Aggregate Collateral Loans by Qualifying Investment Collateral: None.

NOTE 6 Joint Ventures, Partnerships and Limited Liability Companies

None.

NOTE 7 Investment Income

- A.-B. The Plan had no investment income that was excluded from surplus in 2024 or 2023. All of the Plan's investments and the income derived from such investments meet the criteria for admitted receivables.
- C. The gross, nonadmitted and admitted amounts for interest income due and accrued.

 Interest Income Due and Accrued
 Amount

 1. Gross
 \$ 1,381,323

 2. Nonadmitted
 \$ 1,381,323

 3. Admitted
 \$ 1,381,323

- D. The aggregate deferred interest: None.
- E. The cumulative amounts of paid-in-kind (PIK) interest included in the current principal balance: None.

NOTE 8 Derivative Instruments

None.

NOTE 9 Income Taxes

- A. The components of the net deferred tax asset/(liability) at the end of current period are as follows:
 - 1. Components of Net Deferred Tax Asset/(Liability)

		12/31/2024			12/31/2023			Change	
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
	Ordinary	Capital	(Col. 1 + 2) Total	Ordinary	Capital	(Col. 4 + 5) Total	(Col. 1 - 4) Ordinary	(Col. 2 - 5) Capital	(Col. 7 + 8) Total
(a) Gross Deferred Tax Assets	\$ 4,438,121	\$ -	\$ 4,438,121	\$ 2,149,565		\$ 2,149,565	\$ 2,288,556	\$ -	\$ 2,288,556
(b) Statutory Valuation Allowance Adjustment (c) Adjusted Gross Deferred Tax Assets	\$ -	\$ -	\$ -	\$ 2,083,692		\$ 2,083,692	\$(2,083,692)	\$ -	\$(2,083,692)
(1a - 1b)	\$ 4,438,121	\$ -	\$ 4,438,121	\$ 65,873	\$ -	\$ 65,873	\$ 4,372,248	\$ -	\$ 4,372,248
(d) Deferred Tax Assets Nonadmitted (e) Subtotal Net Admitted Deferred Tax Asset	\$ -	\$ -	\$ -			\$ -	\$ -	\$ -	\$ -
(1c - 1d)	\$ 4,438,121	\$ -	\$ 4,438,121	\$ 65,873	\$ -	\$ 65,873	\$ 4,372,248	\$ -	\$ 4,372,248
(f) Deferred Tax Liabilities (g) Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability)	\$ 55,066	\$ -	\$ 55,066	\$ 65,873		\$ 65,873	\$ (10,807)	\$ -	\$ (10,807)
(1e - 1f)	\$ 4,383,055	\$ -	\$ 4,383,055	\$ -	\$ -	\$ -	\$ 4,383,055	\$ -	\$ 4,383,055

		12/31/2024			12/31/2023			Change	
	(1)	(2)	(3) (Col. 1 + 2)	(4)	(5)	(6) (Col. 4 + 5)	(7) (Col. 1 - 4)	(8) (Col. 2 - 5)	(9) (Col. 7 + 8)
	Ordinary	Capital	Total	Ordinary	Capital	Total	Ordinary	Capital	Total
Admission Calculation Components SSAP No. 101, Income Taxes (a) Federal Income Taxes Paid In Prior Years Recoverable Through Loss Carrybacks (b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After	\$ 4,395,004	\$ -	\$ 4,395,004			\$ -	\$ 4,395,004	\$ -	\$ 4,395,004
Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below) 1. Adjusted Gross Deferred Tax Assets Expected to be Realized	\$ 12,457	\$ -	\$ 12,457			\$ -	\$ 12,457	\$ -	\$ 12,457
Following the Balance Sheet Date. 2. Adjusted Gross Deferred Tax Assets Allowed per Limitation	\$ 12,457	\$ -	\$ 12,457			\$ -	\$ 12,457	\$ -	\$ 12,457
Threshold. (c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities. (d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) +	XXX \$ 30,660	* * -	\$24,964,828 \$ 30,660	XXX \$ 65,873	XXX	\$ 7,327,623 \$ 65,873	XXX \$ (35,213)	\$ -	\$17,637,205 \$ (35,213)
2(b) + 2(c))	\$ 4.438.121	\$ -	\$ 4.438.121	\$ 65.873	s -	\$ 65.873	\$ 4.372.248	\$ -	\$ 4.372.248

3. Other Admissibility Criteria

a. Ratio Percentage Used To Determine Recovery Period And Threshold Limitation Amount.

b. Amount Of Adjusted Capital And Surplus Used To Determine Recovery Period And Threshold Limitation In 2(b)2 Above.

2024	2023
343.090%	281.243%

\$ 166,432,188 73,276,225

4.		12/31	12/31/2024		1/2023	Change		
		(1)	(2)	(3)	(4)	(5) (Col. 1 - 3)	(6) (Col. 2 - 4)	
		Ordinary	Capital	Ordinary	Capital	`Ordinary [´]	` Capital [′]	
	Impact of Tax Planning Strategies: (a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage. 1. Adjusted Gross DTAs amount from Note 9A1 (c) 2. Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies 3. Net Admitted Adjusted Gross DTAs amount from Note 9A1(e) 4. Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning	\$ 4,438,121 0.000% \$ 4,438,121	\$ - 0.000%	\$ 65,873 \$ 65,873	\$ - \$ -	\$ 4,372,248 0.000% \$ 4,372,248	\$ - 0.000%	
	strategies	0.000%	0.000%			0.000%	0.000%	

b. Do the Company's tax-planning strategies include the use of reinsurance?

Yes [] No [X]

- Deferred Tax Liabilities Not Recognized: None.
- Current income taxes incurred consist of the following major components:

1.	Current Income Tax (a) Federal (b) Foreign (c) Subtotal (1a+1b) (d) Federal income tax on net capital gains (e) Utilization of capital loss carry-forwards (f) Other (g) Federal and foreign income taxes incurred (1c+1d+1e+1f)
2.	Deferred Tax Assets:

- (1) Discounting of unpaid losses
- (2) Unearned premium reserve
- (3) Policyholder reserves
- (4) Investments
- (5) Deferred acquisition costs
- (6) Policyholder dividends accrual
- (7) Fixed assets
- (8) Compensation and benefits accrual
- (9) Pension accrual
- (10) Receivables nonadmitted
- (11) Net operating loss carry-forward
- (12) Tax credit carry-forward (13) Other

(99) Subtotal (sum of 2a1 through 2a13)

- (b) Statutory valuation allowance adjustment
- (c) Nonadmitted
- (d) Admitted ordinary deferred tax assets (2a99 2b 2c) (e) Capital:
- (1) Investments
 - (2) Net capital loss carry-forward
 - (3) Real estate
 - (4) Other

(99) Subtotal (2e1+2e2+2e3+2e4)

- (f) Statutory valuation allowance adjustment (g) Nonadmitted
- (h) Admitted capital deferred tax assets (2e99 2f 2g)
- (i) Admitted deferred tax assets (2d + 2h)

	(1)		(2)		(3)
	10/21/2021		10/01/0000		(Col. 1 - 2)
_	12/31/2024	_	12/31/2023	_	Change
\$	19,096,591	\$	582,557	\$	18,514,034
\$.			\$.
\$	19,096,591	\$	582,557	\$	18,514,034
\$	-			\$	-
\$	-			\$	-
\$	(91,218)	\$	(1,913)	\$	(89,305)
\$	19,005,373	\$	580,644	\$	18,424,729
\$	1,329,259	\$	1,605,241	\$	(275,982)
\$	-			\$	-
\$	-			\$	-
\$	-			\$	-
\$	-			\$	-
\$	-			\$	-
\$	8,479	\$	55,066	\$	(46,587)
\$	184,016	\$	144,310	\$	39,706
\$	-			\$	-
\$	2,856,816	\$	274,980	\$	2,581,836
\$	-			\$	-
\$	-			\$	-
\$	59,551	\$	69,968	\$	(10,417)
\$	4,438,121	\$	2,149,565	\$	2,288,556
\$	-	\$	2,083,692	\$	(2,083,692)
\$	_		, ,	\$	-
\$	4,438,121	\$	65,873	\$	4,372,248
\$	-			\$	-
\$	-			\$	-
\$	-			\$	-
\$	-			\$	-
\$	-	\$	-	\$	-
\$	-			\$	-
\$	-			\$	-
\$	-	\$	-	\$	-
\$	4,438,121	\$	65,873	\$	4,372,248

3. Deferred Tax Liabilities:			
(a) Ordinary:			
(1) Investments	\$ -		\$ -
(2) Fixed assets	\$ -		\$ -
(3) Deferred and uncollected premium	\$ -		\$ -
(4) Policyholder reserves	\$ -		\$ -
(5) Other	\$ 55,066	\$ 65,873	\$ (10,807)
(99) Subtotal (3a1+3a2+3a3+3a4+3a5)	\$ 55,066	\$ 65,873	\$ (10,807)
(b) Capital:			
(1) Investments	\$ -		\$ -
(2) Real estate	\$ -		\$ -
(3) Other	\$ -		\$ -
(99) Subtotal (3b1+3b2+3b3)	\$ -	\$ -	\$ -
(c) Deferred tax liabilities (3a99 + 3b99)	\$ 55,066	\$ 65,873	\$ (10,807)
4. Net deferred tax assets/liabilities (2i - 3c)	\$ 4,383,055	\$ -	\$ 4,383,055

The Plan is subject to taxation in the United States.

D. Reconciliation of Federal Income Tax Rate to Actual Effective Rate. Among the more significant book to tax adjustments were the following:

	Tax Effect	Effective Tax Rate
Provision computed at statutory rate	\$ 19,482,260	21.00%
Changes in nonadmitted assets	(2,753,379)	-2.97%
Statutory valuation allowance	(2,083,692)	-2.25%
Other	(22,871)	-0.02%
Total	\$ 14,622,318	15.76%
Federal and foreign income taxes incurred	\$ 19,005,373	20.48%
Realized capital gains (losses) tax	-	0.00%
Change in net deferred income taxes	(4,383,055)	-4.72%
Total statutory income taxes	\$ 14,622,318	15.76%

- E. Operating Loss Carry Forwards and Income Taxes Available for Recoupment
 - 1. The amounts, origination dates and expiration dates of operating loss and tax credit carry forward available for tax purposes: None.
 - 2. The following is income tax expense for current year and proceeding years that is available for recoupment in the event of future net losses:

Year	 Amount
2024	\$ 19,096,591
2023	\$ 489,426

- 3. The Plan did not have any aggregate amount of deposits admitted under Section 6603 of the Internal Revenue Code.
- F. Consolidated Federal Income Tax Return

The Plan is included in the consolidated federal income tax return with its ultimate parent, Molina, which constitutes a controlled group. The entities included within the consolidated return are included in NAIC Statutory Statement Schedule Y – Information Concerning Activities of Insurer Members of a Holding Company Group. Federal income taxes are paid to or refunded by Molina pursuant to the terms of a tax-sharing agreement, approved by the Board of Directors, under which taxes approximate the amount that would have been computed on a separate company basis, with the exception of net operating losses and capital losses. For these losses the Plan receives a benefit at the federal rate in the current year for current taxable losses incurred in that year to the extent losses can be utilized in the consolidated federal income tax return of Molina.

Effective tax year 2024, the controlled group was deemed an applicable corporation subject to the Corporate Alternative Minimum Tax ("CAMT"). In accordance with the amended and restated tax sharing agreement, the Plan is excluded from charges for any portion of the group's CAMT and is not allocated any portion of the group's CAMT credit carryover.

Federal income tax paid for 2024 pursuant to the tax sharing agreement was \$11,270,000.

- G. Federal or Foreign Federal Income Tax Loss Contingencies: The Plan does not have any tax loss contingencies for which it is reasonably possible that the total liability will significantly increase within twelve months of the reporting date.
- H. Repatriation Transition Tax: None.
- Alternative Minimum Tax Credit: None.

NOTE 10 Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

- A. Molina has wholly owned operating subsidiaries in various states as indicated in Schedule Y, Parts 1 and 1A.
- B. The Plan received contributions amounting to \$32,500,000 and \$80,000,000 from Molina in the years ended December 31, 2024 and 2023, respectively, principally to provide funding to meet mandated net worth requirements. Molina has agreed to provide additional future funding to the Plan, if necessary, to ensure the Plan's compliance with minimum net worth requirements during the next 12 months.

The Plan has an agreement with Molina whereby Molina provides certain administrative services to the Plan. Expenses incurred relating to this agreement amounted to \$66,305,374 and \$29,115,709 for the years ended December 31, 2024 and 2023, respectively.

- C. Transactions with related party who are not reported on Schedule Y: None.
- D. As of December 31, 2024 and 2023 amounts due to Molina and affiliates totaled \$4,947,673 and \$5,937,240, respectively. Intercompany receivables and payables are generally settled on a monthly basis.
- E. The Plan has a services agreement with Molina, as described in Note 10B. above
- F. The Plan is not a guarantor and does not participate in any undertakings.
- G. As indicated in Note 10.A. above, the Plan is a wholly owned subsidiary of Molina. The entities under common ownership of Molina are indicated in Schedule Y, Parts 1 and 1A.
- H. Amount Deducted from the Value of Upstream Intermediate Entity or Ultimate Parent Owned: None.
- I. Investments in SCA that Exceed 10% of Admitted Assets: None.

- J. Investments in Impaired SCAs: None
- K. Investment in Foreign Insurance Subsidiary: None
- L. Investment in Downstream Noninsurance Holding Company: None.
- M. All SCA Investments: None.
- N. Investment in Insurance SCAs: None.
- O. SCA or SSAP 48 Entity Loss Tracking: None.

NOTE 11 Debt

- A. Debt Including Capital Notes: None.
- B. Federal Home Loan Bank Agreements: None.

NOTE 12 Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

- A.-D. Debt Including Capital Notes: None
- E. Defined Contribution Plan: See Note 12.G.
- F. Multiemployer Plans: None.
- G. Consolidated/Holding Company Plans: The employees of the Plan are eligible to participate in a defined contribution 401(k) plan sponsored by Molina subject to the participation eligibility set forth in the plan. Eligible employees are allowed to contribute up to the maximum allowed by law. The Plan matches 100% up to the first 4% of compensation contributed by the employees, up to IRS recognized limits, subject to a one-year cliff vesting requirement. The Plan has no legal obligation to provide benefits under the plan. The Plan's expense recognized in connection with the 401(k) plan was \$1,057,429 and \$518,204 for the years ended December 31, 2024 and 2023, respectively.
- H. Postemployment Benefits and Compensated Absences: None.
- I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17): None.

NOTE 13 Capital and Surplus, Dividend Restrictions and Quasi-Reorganizations

- A. The Plan has 100 shares of no par value common stock authorized, 100 shares issued and outstanding. All issued and outstanding shares of common stock are held by Molina
- B. Preferred stock: None.
- C. Dividend restrictions: Without prior approval of its domiciliary commissioner or Division of insurance, dividends to shareholders must be paid from earned surplus amounts and are limited to the lessor of ten percent of the companies surplus or the net income for the 12 month period ending as of the prior year as set forth in the laws of the Company's state of incorporation, lowa. Also, any dividend paid from other than earned surplus, shall be considered an extraordinary dividend and will need approval of the Insurance Commissioner.
- D. Dividends paid by the Plan to Molina during the years 2024 and 2023, respectively, were as follows: Refer to Note 10B.
- E. Subject to the limitations of 13(C), no restrictions have been placed on the portion of the Plan's profits that may be paid as ordinary dividends to Molina.
- F. Restrictions placed on unassigned funds (surplus): None.
- G. Advances to surplus not repaid: None
- H. Stock held for special purposes: None.
- I. Changes in the balance of special surplus funds: None.
- J. The portion of unassigned surplus or deficit, excluding net income and dividends, represented or reduced by each item below is as follows:

	 2024	 2023
Nonadmitted assets	\$ (14,650,571)	\$ (1,539,241)
Totals	\$ (14,650,571)	\$ (1,539,241)

- K. The Company issued the following surplus debentures or similar obligations: None.
- L. The impact of any restatement due to prior quasi-reorganizations is as follows: None.
- M. The effective dates of all quasi-reorganizations in the prior 10 years: None.

NOTE 14 Liabilities, Contingencies and Assessments

- A. Contingent Commitments: The Plan has no contingent commitments.
- B. Assessments: None.
- C. Gain Contingencies: None.
- D. Claims related extra contractual obligations and bad faith losses stemming from lawsuits: None.
- E. Joint and Several Liabilities: None.
- F. All Other Contingencies: From time to time, the Plan may be involved in legal actions in the normal course of business, some of which involve a demand for both compensatory and punitive damages not covered by insurance. Currently, there are no pending or threatened actions which, to the knowledge and in the opinion of management and the Plan's counsel, would have a material adverse effect on the Plan's financial position, results of operations or cash flow.

The Plan routinely evaluates the collectability of all receivable amounts included in the statutory basis statements of admitted assets, liabilities, and capital and surplus. Impairment reserves are established for those amounts where collectability is uncertain. Based on the Plan's past experience, exposure related to uncollectible balances and the potential of loss for those balances not currently reserved for is not material to the Plan's financial position, results of operation or cash flow.

The Plan recognizes the financial statement benefit of a tax position after determining that the relevant tax authority would more likely than not sustain the position following an audit, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Interest and penalties, if incurred, are recognized in the statutory basis statements of revenue and expenses as federal income tax expense. The Plan did not have any tax loss contingency liability as of December 31, 2024. The Plan has not recognized any interest or penalties for the years ended December 31, 2024 and 2023.

There are no assets that the Plan considers to be impaired at December 31, 2024 and 2023.

NOTE 15 Leases

- A. Lessee Operating Lease:
 - (1) The Plan leases office facilities and equipment under noncancelable long-term operating leases. Some of the leases contain escalation clauses and renewal options. Rental expense relating to these leases totaled \$71,535 and \$35,450 for the years ended December 31, 2024 and 2023, respectively.
 - (2) a. At January 1, 2025, the minimum aggregate rental commitments are as follows:

	Leases
1. 2025	\$ 70,777
2. 2026	\$ 72,209
3. 2027	\$ 74,205
4. 2028	\$ 76,432
5. 2029	\$ 19,248
6. Thereafter	\$ -
7. Total (sum of 1 through 6)	\$ 312,871

- b. Total of Minimum Rentals to be Received in the Future under Noncancelable Subleases: None
- (3) For Sale-Leaseback Transactions: None.
- B Lessor Leases: None

NOTE 16 Information About Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of Credit Risk

None

NOTE 17 Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

- A. Transfers of Receivables Reported as Sales: None.
- B. Transfer and Servicing of Financial Assets: None.
- C. Wash Sales: None.

NOTE 18 Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

- A. Administrative Services Only Plans: None.
- B. Administrative Services Contract Plans: None.

NOTE 19 Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

None.

NOTE 20 Fair Value Measurements

The NAIC SAP defines fair value, establishes a framework for measuring fair value, and outlines the disclosure requirements related to fair value measurements. The fair value hierarchy is as follows:

Level 1 – Certain inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 – Certain inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specific (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability. Level 2 inputs include the following:

- Quoted prices for similar assets in active markets;
- Quoted prices for identical or similar assets in nonactive markets (few transactions, limited information, noncurrent prices, high variability over time, etc.);
- Inputs other than quoted prices that are observable for the asset (interest rates, yield curves, volatilities, default rates, etc.);
- Inputs that are derived principally from or corroborated by other observable market data.

Level 3 – Certain inputs are unobservable inputs for the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that relevant observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.

Bonds and short-term investments are based on quoted market prices, where available.

A. Fair Value Measurements

(1) Fair Value Measurements at Reporting Date: The Plan's assets measured and reported at fair value on a recurring basis are listed in the tables below. The Plan receives monthly statements from investment brokers that provide market pricing. There were no transfers between Level 1 and Level 2 of the fair value hierarchy.

2024:

Description for each class of asset or liability	(Level 1)	(Level 2)	(Level 3)		Net Asset Valu (NAV)	ie	Total
a. Assets at fair value							
Exempt money market mutual funds	\$ 390,234	\$ -	\$	-	\$	-	\$ 390,234
Other money market mutual funds	\$ 131,717,062	\$ -	\$	-	\$	-	\$ 131,717,062
Total assets at fair value/NAV	\$ 132,107,296	\$ _	\$	-	\$	-	\$ 132,107,296

Description for each class of asset or liability	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Total
b. Liabilities at fair value					
Total liabilities at fair value	\$ -	\$ -	\$ -	\$ -	\$ -

2023:

Description for each class of asset	(Level 1)	(Level 2)	(Level 3)		Net Asset Value (NAV)	Total
a. Assets at fair value						
Exempt money market mutual funds	\$ 76,083,539	\$ -	\$	-	\$ -	\$ 76,083,539
Other money market mutual funds	\$ 145,315,546	\$ -	\$	-	\$ -	\$ 145,315,546
Total assets at fair value/NAV	\$ 221,399,085	\$ -	\$	- [\$ -	\$ 221,399,085

- (2) Fair Value Measurements in Level 3 of the Fair Value hierarchy: None.
- (3) Policies for Determining when Transfers Between Levels are Recognized: The actual date of the event or change in circumstances that caused the transfer.
- (4) Description of Valuation Techniques and Inputs Used in Fair Value Measurement: Level 2 financial instruments include investments that are traded frequently though not necessarily daily. Fair value for these securities is determined using a market approach based on quoted prices for similar securities in active markets or quoted prices for identical securities in inactive markets.
- (5) Derivative assets and liabilities: None.
- 3. Fair Value Reporting under SSAP No. 100, Fair Value Measurements, and Other Accounting Pronouncements: In addition to the financial instruments listed below, the Plan's statutory basis balance sheets typically include the following financial instruments: investment income due and accrued, federal income tax recoverable (payable), receivables, and current liabilities. The Plan believes the carrying amounts of these financial instruments approximate the fair value of these financial instruments because of the relatively short period of time between the origination of the instruments and their expected realization or payment.
- C. Aggregate fair value for all financial instruments and the level within the fair value hierarchy in which the fair value measurements in their entirety fall.

The aggregate fair value hierarchy of all financial instruments as of December 31, 2024 and 2023 are presented in the tables below:

2024

2024.												
Type of Financial		Aggregate								Ne	et Asset Value	Not Practicable
Instrument		Fair Value	Α	dmitted Assets	(Level 1)	(Level 2)		(Level 3)		(NAV)		(Carrying Value)
Exempt money market												
mutual funds	\$	390,234	\$	390,234	\$ 390,234	\$	-	\$	-	\$	-	
Other money market												
mutual funds	\$	131,717,061	\$	131,717,061	\$ 131,717,061	\$	-	\$	-	\$	-	
Open depositories	\$	59,531,661	\$	59,531,661	\$ 59,531,661	\$	_	\$	-	\$	-	
Special revenue &												
special assessments	\$	13,088,927	\$	13,179,854	\$ -	\$	13,088,927	\$	-	\$	-	
Industrial &												
miscellaneous	\$	68,019,959	\$	68,409,934	\$ -	\$	68,019,959	\$	-	\$	-	
Political subdivisions	\$	239,118	\$	237.789	\$ _	\$	239.118	\$	_	\$	-	
Total financial	ľ	-,	l	,			,	l				
instruments	\$	272,986,960	\$	273,466,533	\$ 191,638,956	\$	81,348,004	\$	-	\$	-	

2023:

Type of Financial Instrument	Aggregate Fair Value	A	dmitted Assets	(Level 1)	(Level 2)	(Level 3)	Net	Asset Value (NAV)		Not Practicable (Carrying Value)
Exempt money market mutual funds	\$ 76,083,539	\$	76,083,539	\$ 76,083,539	\$ _	\$ _	\$	_		\$ -
Other money market mutual funds	\$ 145,315,546	\$	145,315,546	\$ 145,315,546						
Open depositories Total financial	\$ (10,528,568)	\$	(10,528,568)	\$ (10,528,568)						
instruments	\$ 210,870,517	\$	210,870,517	\$ 210,870,517	\$ _	\$ -	\$	-	1:	\$ -

- D. Not Practicable to Estimate Fair Value: None.
- E. NAV Practical Expedient Investments: None.

NOTE 21 Other Items

- A. Unusual or Infrequent Items: None.
- B. Troubled Debt Restructuring: Debtors: None.
- C. Other Disclosures

Stock Plans

Under an equity incentive plan adopted by Molina, the Plan's employees may be awarded Molina restricted stock or other equity incentives. Restricted stock awards generally vest in equal annual installments over periods of up to four years from the date of grant.

Molina has an employee stock purchase plan under which the eligible employees of the Plan may purchase common shares at 85% of the lower of the fair market value of Molina's common stock on either the first or last trading day of each six-month offering period. Each participant is limited to a maximum purchase of \$25,000 (as measured by the fair value of the stock acquired) per year through payroll deductions.

- D. Business Interruption Insurance Recoveries: None.
- E. State Transferable and Non-transferable Tax Credits: None.
- F. Subprime Mortgage Related Risk Exposure: None.
- G. Retained Assets: None.
- H. Insurance-Linked Securities Contracts: None.
- I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy:

NOTE 22 Events Subsequent

Type I – Recognized Subsequent Events: None.

Type II – Nonrecognized Subsequent Events: None.

The Plan evaluated its December 31, 2024 statutory basis financial statements for subsequent events through February 26, 2025, the date the statutory basis financial statements were available to be issued. The Plan is not aware of any subsequent events that would require recognition or disclosure in these statutory basis financial

NOTE 23 Reinsurance

Ceded Reinsurance Report

Section 1 - General Interrogatories

- (1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly, by the company or by any representative, officer, trustee, or director of the company? No.
- (2) Have any policies issued by the company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, a beneficiary, a creditor or any other person not primarily engaged in the insurance business? No.

Section 2 - Ceded Reinsurance Report - Part A

- (1) Does the company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credits? No.
- (2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies? No.

Section 3 - Ceded Reinsurance Report - Part B

- (1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the company may consider the current or anticipated experience of the business reinsured in making this estimate. \$0
- (2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the company as of the effective date of the agreement? No.
- Uncollectible Reinsurance: None
- C Commutation of Reinsurance Reflected in Income and Expenses: None.
- Certified Reinsurer Rating Downgraded or Status Subject to Revocation: None. D.
- Reinsurance Credit: None

NOTE 24 Retrospectively Rated Contracts & Contracts Subject to Redetermination

A.-C. The business of the Plan that is subject to retrospective rating and redetermination features is as follows:

Medicaid Program

Medical Cost Floors (Medical Loss Ratio, or MLR): For certain Medicaid premiums, amounts may be returned to HHS, if certain minimum amounts are not spent on defined medical care costs.

Risk Corridors: The Plan is subject to a medical loss ratio corridor with HHS, applicable to the Plan's Medicaid program. The Plan estimates accrued retrospective premium based on the experience to date using a mathematical approach.

Pay for Performance: Under the Plan's contract with HHS, 2% of Medicaid premiums are withheld and paid to the Plan subject to certain performance bonus measures being met. Recognition of quality incentive premium revenue is subject to the use of estimates for the achievement of the performance measures

The Plan had net premiums written of \$1,512,884,014 and \$633,982,781 for its Medicaid (including CHIP) business for the years ended December 31, 2024 and 2023, representing 100% of total net premiums written in both years.

Estimated accrued retrospective premiums due from the Plan are recorded in aggregate health policy reserves on Page 3 Line 4 and as an adjustment to change in reserve for rate credits on Page 4 Line 3.

- Medical loss ratio rebates required pursuant to the Public Health Service Act: None.
- Risk Sharing Provisions of the Affordable Care Act
 (1) Did the reporting entity write accident and health insurance premium which is subject to the Affordable Care Act risk sharing provisions (YES/NO)?

Yes [] No [X]

- (2) Impact of Risk Sharing Provisions of the Affordable Care Act on Admitted Assets, Liabilities and Revenue for the Current Year:
- (3) Roll forward of prior year ACA risk sharing provisions for the following asset (gross of any nonadmission) and liability balances along with the reasons for adjustments to prior year balance: None.

NOTE 25 Change in Incurred Claims and Claim Adjustment Expenses

The liabilities for claims unpaid and accrued medical incentive pool and bonus amounts, net of health care receivables, as of December 31, 2023 were \$157,889,363. As of December 31, 2024, \$137,183,267 has been paid for incurred claims attributable to insured events of prior years. Reserves remaining for prior years, net of health care receivables are now \$199,451, as a result of re-estimation of unpaid claims principally on the Medicaid line of business. Therefore, there has been a \$20,506,645 favorable prior-year development since December 31, 2023 to December 31, 2024. The favorable development is generally the result of ongoing analysis of recent loss development trends primarily due to lower than expected utilization of medical services. Consequently, the ultimate costs recognized in 2024, as claims payments were processed, were lower than the Plan's original estimates in 2023.

The liabilities for claim adjustment expenses as of December 31, 2023 were \$1,022,522. As of December 31, 2024, the Plan incurred and paid claims adjustment expenses of \$46,993,166 and \$47,072,345, respectively. The liabilities for claims adjustment expenses are now \$943,343

Information about Significant Changes in Methodologies and Assumptions: The Plan did not make any significant changes in methodologies and assumptions used in the calculation of the liability for claims unpaid and unpaid claim adjustment expenses in 2024 or 2023

NOTE 26 Intercompany Pooling Arrangements

None.

NOTE 27 Structured Settlements

None

NOTE 28 Health Care Receivables

A. Pharmaceutical Rebate Receivables

Date	Estimated Pharmacy Rebates as Reported on Financial Statements	Pharmacy bates as Billed or Otherwise Confirmed	Re	ctual Rebates eceived Within Days of Billing	Re	ctual Rebates ceived Within to 180 Days of Billing	R	ctual Rebates eceived More nan 180 Days After Billing
12/31/2024	\$ 71,212	\$ -	\$	-	\$	-	\$	-
09/30/2024	\$ 65,211	\$ 73,598	\$	-	\$	-	\$	-
06/30/2024	\$ 45,480	\$ 70,636	\$	-	\$	71,746	\$	-
03/31/2024	\$ 68,172	\$ 42,947	\$	-	\$	51,424	\$	3,741
12/31/2023	\$ 42,519	\$ 41,931	\$	-	\$	51,752	\$	(3,885)
09/30/2023	\$ -	\$ 63,045	\$	-	\$	42,202	\$	(15,519)
06/30/2023	\$ -	\$ -	\$	-	\$	-	\$	-
03/31/2023	\$ -	\$ -	\$	-	\$	-	\$	-
12/31/2022	\$ -	\$ -	\$	-	\$	-	\$	-
09/30/2022	\$ -	\$ -	\$	-	\$	-	\$	-
06/30/2022	\$ -	\$ -	\$	-	\$	-	\$	-

B. Risk-Sharing Receivables: None.

NOTE 29 Participating Policies

None.

NOTE 30 Premium Deficiency Reserves

1. Liability carried for premium deficiency reserves \$ - \$ - \$ - 2. Date of the most recent evaluation of this liability 12/31/2024 12/31/2023 3. Was anticipated investment income utilized in the calculation? Yes [X] No [] Yes [X] No []

NOTE 31 Anticipated Salvage and Subrogation

None.

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES GENERAL

1.1	Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of whi is an insurer?		Yes [X] No []	
	If yes, complete Schedule Y, Parts 1, 1A, 2 and 3.				
1.2	If yes, did the reporting entity register and file with its domiciliary State Insurance Commissioner, Director or Superintendent or with such regulatory official of the state of domicile of the principal insurer in the Holding Company System, a registration statement providing disclosure substantially similar to the standards adopted by the National Association of Insurance Commissioners (NAIC) in its Model Insurance Holding Company System Regulatory Act and model regulations pertaining thereto, or is the reporting entity subject to standards and disclosure requirements substantially similar to those required by such Act and regulations?	es [X] No [] N/A []
1.3	State Regulating?		low	a	
1.4	Is the reporting entity publicly traded or a member of a publicly traded group?		Yes [X] No []	
1.5	If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group		11799	929	
2.1	Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity?		Yes [] No [X]	
2.2	If yes, date of change:				
3.1	State as of what date the latest financial examination of the reporting entity was made or is being made.		12/31/	2021	
3.2	State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity. This date should be the date of the examined balance sheet and not the date the report was completed or released		12/31/	2021	
3.3	State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance sheet date).		05/01/	2023	
3.4	By what department or departments? Iowa Insurance Division				
3.5	Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial statement filed with Departments?	es [] No [] N/A [X]
3.6	Have all of the recommendations within the latest financial examination report been complied with?	es [] No [] N/A [X]
4.1	During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than salaried employees of the reporting entity) receive credit or commissions for or conta substantial part (more than 20 percent of any major line of business measured on direct premiums) of: 4.11 sales of new business?		Yes [] No [X]	
4.2	4.12 renewals? During the period covered by this statement, did any sales/service organization owned in whole or in part by the reporting entity or an affiliar receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:		Yes [] No [X]	
	4.21 sales of new business?] No [X]	
5.1	Has the reporting entity been a party to a merger or consolidation during the period covered by this statement?		Yes [] No [X]	
5.2	If yes, provide the name of the entity, NAIC company code, and state of domicile (use two letter state abbreviation) for any entity that has ceased to exist as a result of the merger or consolidation.				
	1 Name of Entity NAIC Company Code State of Domicile				
6.1	Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended revoked by any governmental entity during the reporting period?		Yes [] No [X]	
6.2	If yes, give full information				
7.1	Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity?		Yes [] No [X]	
7.2	If yes, 7.21 State the percentage of foreign control	·····_			- %
	1 2 Nationality Type of Entity				

8.1 8.2	Is the company a subsidiary of a depository institution holding compar If the response to 8.1 is yes, please identify the name of the DIHC.					Yes []	No [[X]	
8.3 8.4	Is the company affiliated with one or more banks, thrifts or securities fill response to 8.3 is yes, please provide below the names and location federal financial regulatory services agency [i.e. the Federal Reserve Federal Deposit Insurance Corporation (FDIC) and the Securities Excregulator.	ns (city and state of the main office) of any affiliates Board (FRB), the Office of the Comptroller of the Co	regulate	ed by a (OCC), th	 ne	Yes []	No [[X]	
	1	2	3	4	5	6	1			
	Affiliate Name	Location (City, State)	FRB	OCC	FDIC	SEC	_			
8.5 8.6	Is the reporting entity a depository institution holding company with sig Federal Reserve System or a subsidiary of the depository institution helf response to 8.5 is no, is the reporting entity a company or subsidiary Federal Reserve Board's capital rule?	olding company? y of a company that has otherwise been made subje	ect to the	 •		Yes [] No [•			
9.	What is the name and address of the independent certified public according to the independent certified public acc	<u> </u>								
10.1	Grant Thornton LLP, 2501 E. Enterprise Avenue, Suite 300, Appleton, Has the insurer been granted any exemptions to the prohibited non-au requirements as allowed in Section 7H of the Annual Financial Report law or regulation?	udit services provided by the certified independent p ting Model Regulation (Model Audit Rule), or substa	oublic ac intially s	countant	t ite	Yes []	No [[X]	
10.3	Has the insurer been granted any exemptions related to the other requallowed for in Section 18A of the Model Regulation, or substantially sin If the response to 10.3 is yes, provide information related to this exem	milar state law or regulation?ption:				Yes []	No [[X]	
10.5	Has the reporting entity established an Audit Committee in compliance					1 No I	V 1	N/	۸г	1
10.6	If the response to 10.5 is no or n/a, please explain. The Plan is a direct wholly owned subsidiary of Molina. Molina is a pul Oxley Act. An Audit Committee is maintained at the Corporate level (N	blicly traded company and is subject to compliance	with the	Sarbane	es-) NO [۸]	11//	n [1
11.	What is the name, address and affiliation (officer/employee of the reportirm) of the individual providing the statement of actuarial opinion/certi Benjamin Lynam, FSA, MAAA, Chief Actuary, 200 Oceangate, Suite 1	fication?			Ü					
12.1	Does the reporting entity own any securities of a real estate holding co	ompany or otherwise hold real estate indirectly? estate holding company				Yes []	No [[X]	
		rcels involved								
		justed carrying value			\$	·				
12.2	If yes, provide explanation									
13. 13.1	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTIT What changes have been made during the year in the United States n	IES ONLY: nanager or the United States trustees of the reportion	ng entity	?						
13.2	Does this statement contain all business transacted for the reporting e					Yes []	No [[]	
13.3	Have there been any changes made to any of the trust indentures duri	9 ,				Yes []	No [[]	
13.4	If answer to (13.3) is yes, has the domiciliary or entry state approved the senior officers (principal executive officer, principal financial of] No []	N/A	Α[]
14.1	similar functions) of the reporting entity subject to a code of ethics, what a. Honest and ethical conduct, including the ethical handling of actual relationships; b. Full, fair, accurate, timely and understandable disclosure in the period.	ich includes the following standards?or apparent conflicts of interest between personal a	and profe			Yes [X]	No [[]	
	c. Compliance with applicable governmental laws, rules and regulation	, , , , ,	,							
	d. The prompt internal reporting of violations to an appropriate person	or persons identified in the code; and								
14.11	e. Accountability for adherence to the code. If the response to 14.1 is No, please explain:									
14.2	Has the code of ethics for senior managers been amended?					Yes [X	. 1	No 1	[]	
	If the response to 14.2 is yes, provide information related to amendme On January 24, 2024, Molina Healthcare, Inc. ("Molina") amended its description of Molina's mandatory training process for employees on to Program and its policies and procedures, and fraud, waste, and abuse required trainings on time may be subject to disciplinary action, up to a	ent(s). Code of Business Conduct and Ethics (the "Code") opics including but not limited to the Code, Molina's e. The amendments clarify that employees who fail	to includ	le a ance			•		. ,	
14.3 14.31	In addition, Molina made certain other changes to the Code, including Have any provisions of the code of ethics been waived for any of the s If the response to 14.3 is yes, provide the nature of any waiver(s).	•				Yes []	No [[X]	

 Is the reporting entity the beneficiary of a Letter of Credit that is unrelated to reinsurance where the issuing or confirming bank is not on the SVO Bank List? If the response to 15.1 is yes, indicate the American Bankers Association (ABA) Routing Number and the name of the issuing or confirming bank of the Letter of Credit and describe the circumstances in which the Letter of Credit is triggered. 		Yes []	No [X			
t	oank of the Lette	er of Credit and describe the circumstances in which the Lette	er of Credit is triggered	l.			
	1 American Bankers Association (ABA) Routing	2		3		4	
-	Number	Issuing or Confirming Bank Name		nat Can Trigger the Letter of Credit		oun	
L							
		BOARD O	F DIRECTORS	(
		or sale of all investments of the reporting entity passed upon e			Yes []	No [
	Does the reporting	ng entity keep a complete permanent record of the proceeding	gs of its board of direc	ctors and all subordinate committees	Yes [X]	No [
þ	Has the reporting part of any of its	g entity an established procedure for disclosure to its board of officers, directors, trustees or responsible employees that is i	f directors or trustees n conflict or is likely to	of any material interest or affiliation on the conflict with the official duties of such	Yes [X		
ŀ	De15011?				ies į n	, ,	NO [
		FINA	ANCIAL				
H	Has this stateme	ent been prepared using a basis of accounting other than Stat ciples)?	tutory Accounting Prin	ciples (e.g., Generally Accepted	Yes [1	No [
		aned during the year (inclusive of Separate Accounts, exclusiv	ve of policy loans):	20.11 To directors or other officers	.\$		
				20.12 To stockholders not officers	.\$		
				20.13 Trustees, supreme or grand (Fraternal Only)	\$		
٦	Total amount of	loans outstanding at the end of year (inclusive of Separate Ac	ccounts, exclusive of				
p	oolicy loans):			20.21 To directors or other officers			
				20.22 To stockholders not officers 20.23 Trustees, supreme or grand (Fraternal Only)	•		
۷	Were any assets	s reported in this statement subject to a contractual obligation reported in the statement?	to transfer to another	party without the liability for such			
		amount thereof at December 31 of the current year:		21.21 Rented from others	\$		
				21.22 Borrowed from others			
				21.23 Leased from others			
				21.24 Other	\$		
	Does this statem	nent include payments for assessments as described in the Alation assessments?	nnual Statement Instr	uctions other than guaranty fund or	γ _{ας} [1	No I
	f answer is yes:	anon assessments:	22.	21 Amount paid as losses or risk adjustment	\$		
				22 Amount paid as expenses			
	Daga tha ranarti	ng entity report any amounts due from parent, subsidiaries or		23 Other amounts paid			
	•	ny amounts receivable from parent included in the Page 2 am	•			-	
	Does the insurer	rutilize third parties to pay agent commissions in which the an	mounts advanced by t	he third parties are not settled in full within	Yes [
		o 24.1 is yes, identify the third-party that pays the agents and			.00 [
Г			Is the				
		Name of Third-Party	Third-Party Ager a Related Party (Yes/No)				
		Traine of Time Cary	, ,				
		INVE	STMENT				
		11442					
١	Were all the stoo	cks, bonds and other securities owned December 31 of currer		e reporting entity has exclusive control, in addressed in 25.03)	Yes [,	

25.02	If no, give full and complete information, relating thereto					
25.03	For securities lending programs, provide a description of the program i whether collateral is carried on or off-balance sheet. (an alternative is t					
25.04	For the reporting entity's securities lending program, report amount of or Instructions.	collateral for conforming programs as outlined in the Risk-Based Capital				
25.05	For the reporting entity's securities lending program, report amount of o	collateral for other programs	\$			
25.06	Does your securities lending program require 102% (domestic securities outset of the contract?] No	[] N	I/A [X
25.07	Does the reporting entity non-admit when the collateral received from t	the counterparty falls below 100%? Yes [] No	[] N	I/A [X
25.08	Does the reporting entity or the reporting entity's securities lending age conduct securities lending?] No	[] N	/A [X
25.09	For the reporting entity's securities lending program state the amount of	of the following as of December 31 of the current year:				
	25.092 Total book/adjusted carrying value of reinveste25.093 Total payable for securities lending reported or	reported on Schedule DL, Parts 1 and 2ed collateral assets reported on Schedule DL, Parts 1 and 2n the liability page	\$			
26.1	control of the reporting entity or has the reporting entity sold or transfer		Yes	[] No	[X]
26.2	If yes, state the amount thereof at December 31 of the current year:	26.21 Subject to repurchase agreements	\$			
26.3	For category (26.26) provide the following:	20.32 Outer	\$			
26.3	For category (26.26) provide the following: 1 Nature of Restriction	2 Description	F	3 Amou	ınt	
26.3	1	2 Description		3 Amou	ınt	
26.3	Nature of Restriction Does the reporting entity have any hedging transactions reported on Science (Control of Science (Contro	2 Description chedule DB?	Yes	3 \mou	unt 	
27.1 27.2	Nature of Restriction Does the reporting entity have any hedging transactions reported on Solf yes, has a comprehensive description of the hedging program been if no, attach a description with this statement.	Description chedule DB?	Yes	3 \mou	unt 	
27.1 27.2 INES 2	1 Nature of Restriction Does the reporting entity have any hedging transactions reported on Solid yes, has a comprehensive description of the hedging program been of the first of the first of the hedging program been of the hedging program be	Description chedule DB?	Yes] No	3 AMOU 	ınt] No] N	[X] A/I
27.1 27.2 INES 2 27.3	1 Nature of Restriction Does the reporting entity have any hedging transactions reported on Solid yes, has a comprehensive description of the hedging program been of the fine, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ON Does the reporting entity utilize derivatives to hedge variable annuity groups.	Description chedule DB?	Yes	3 AMOU 	ınt] No] N	
27.1 27.2 INES 2	1 Nature of Restriction Does the reporting entity have any hedging transactions reported on Solf yes, has a comprehensive description of the hedging program been of the fino, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ON Does the reporting entity utilize derivatives to hedge variable annuity golf the response to 27.3 is YES, does the reporting entity utilize: 27.41 Sp 27.42 Pe	Description chedule DB? made available to the domiciliary state?	Yes Yes Yes Yes	3 AMOU [[No No No No No No No No	[X] A/X [X] [] []
27.1 27.2 INES 2 27.3	Does the reporting entity have any hedging transactions reported on Solf yes, has a comprehensive description of the hedging program been of the fino, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ON Does the reporting entity utilize derivatives to hedge variable annuity good of the response to 27.3 is YES, does the reporting entity utilize: 27.41 Sp 27.42 Pe 27.43 Ott By responding YES to 27.41 regarding utilizing the special accounting following: The reporting entity has obtained explicit approval from the does the dedging strategy subject to the special accounting provisions. Actuarial certification has been obtained which indicates that the reserves and provides the impact of the hedging strategy with Financial Officer Certification has been obtained which indicates.	Description chedule DB?	Yes] No Yes Yes Yes Yes	3 Amou [[No No No No No No No No	[X] AVI
27.1 27.2 INES 2 27.3 27.4	Does the reporting entity have any hedging transactions reported on Solf yes, has a comprehensive description of the hedging program been of the fino, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ON Does the reporting entity utilize derivatives to hedge variable annuity good of the response to 27.3 is YES, does the reporting entity utilize: 27.41 Sp 27.42 Pe 27.43 Ott By responding YES to 27.41 regarding utilizing the special accounting following: The reporting entity has obtained explicit approval from the does the dedging strategy subject to the special accounting provisions. Actuarial certification has been obtained which indicates that the reserves and provides the impact of the hedging strategy with Financial Officer Certification has been obtained which indicated Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and strategy and strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and strategy and strategy within VM-21 and strategy Defined Hedging Strategy Within VM-21 and strategy De	Description chedule DB?	Yes] No Yes Yes Yes Yes Yes	3 AAMOU [[No No No No	[X] AVI
27.1 27.2 INES 2 27.3 27.4	Nature of Restriction Nature of Restriction If yes, has a comprehensive description of the hedging program been of the life no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ON Does the reporting entity utilize derivatives to hedge variable annuity go of the response to 27.3 is YES, does the reporting entity utilize: 27.41 Sp 27.42 Pe 27.43 Ott By responding YES to 27.41 regarding utilizing the special accounting following: The reporting entity has obtained explicit approval from the does the degree of the special accounting provisions. Actuarial certification has been obtained which indicates that the reserves and provides the impact of the hedging strategy with Financial Officer Certification has been obtained which indicated Hedging Strategy within VM-21 and that the Clearly Defined His actual day-to-day risk mitigation efforts. Were any preferred stocks or bonds owned as of December 31 of the dissuer, convertible into equity?	Description chedule DB?	Yes Yes Yes Yes Yes Yes Yes Yes	3 AAMOU	No No No No No No No No	[X] AVI
27.1 27.2 INES 2 27.3 27.4 27.5	Nature of Restriction Nature of Restriction If yes, has a comprehensive description of the hedging program been of the life no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ON Does the reporting entity utilize derivatives to hedge variable annuity good of the response to 27.3 is YES, does the reporting entity utilize: 27.41 Sp 27.42 Pe 27.43 Ott By responding YES to 27.41 regarding utilizing the special accounting following: The reporting entity has obtained explicit approval from the does. Hedging strategy subject to the special accounting provisions. Actuarial certification has been obtained which indicates that the reserves and provides the impact of the hedging strategy with Financial Officer Certification has been obtained which indicates that the reserves and provides the impact of the hedging strategy with the Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and t	Description chedule DB?	Yes Yes Yes Yes Yes Yes Yes	3 Amou	No No No No No No No No	[X] AVI
27.1 27.2 INES 2 27.3 27.4 27.5	Nature of Restriction Nature of Restriction If yes, has a comprehensive description of the hedging program been of the life no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ON Does the reporting entity utilize derivatives to hedge variable annuity good of the response to 27.3 is YES, does the reporting entity utilize: 27.41 Sp 27.42 Pe 27.43 Ott By responding YES to 27.41 regarding utilizing the special accounting following: The reporting entity has obtained explicit approval from the does. Hedging strategy subject to the special accounting provisions. Actuarial certification has been obtained which indicates that the reserves and provides the impact of the hedging strategy with Financial Officer Certification has been obtained which indicates that the reserves and provides the impact of the hedging strategy with the Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy within VM-21 and t	Description chedule DB?	Yes Yes Yes Yes Yes Yes Yes	3 Amou	No No No No No No No No	[X] AVI [X] [X] [X] [X] [X] [X] [X] [X] [X] [X]

GENERAL INTERROGATORIES

9.02	For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location
	and a complete explanation:

	Name(s)	Location(s)	Comple	ete Explanation(s)	
				1	_
3	Have there been any changes, including name change	s, in the custodian(s) identified in 29.01 during th	e current year?	Yes [] No	[X]
4	If yes, give full and complete information relating there	0:			
	1 Old Custodian	2 Now Custodian Date of	3 f Change	4 Pageon	

29.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. This includes both primary and sub-advisors. For assets that are managed internally by employees of the reporting entity, note as such. ["...that have access to the investment accounts"; "...handle securities"]

1	2
Name of Firm or Individual	Affiliation
New England Asset Management, Inc.	U

29.0597 For those firms/individuals listed in the table for Question 29.05, do any firms/individuals unaffiliated with the reporting entity (i.e., designated with a "U") manage more than 10% of the reporting entity's invested assets?

29.06 For those firms or individuals listed in the table for 29.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

1	2	3	4	5
				Investment
				Management
Central Registra	on			Agreement
Depository Num	er Name of Firm or Individual	Legal Entity Identifier (LEI)	Registered With	(IMA) Filed
105900	New England Asset Management, Inc.	KUR85E5PS4GQFZTFC130	SEC	NO

30.1	Does the reporting entity have any diversified mutual funds reported in Schedule D - Part 2 (diversified according to the Securities and				
	Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5(b)(1)])?	Yes []	No	[X]

30.2 If yes, complete the following schedule:

29.03 29.04

1	2	3
		Book/Adjusted
CUSIP#	Name of Mutual Fund	Carrying Value
30.2999 - Total		

30.3 For each mutual fund listed in the table above, complete the following schedule:

1	2	3	4
		Amount of Mutual	
		Fund's Book/Adjusted	
		Carrying Value	
	Name of Significant Holding of the	Attributable to the	Date of
Name of Mutual Fund (from above table)	Mutual Fund	Holding	Valuation

GENERAL INTERROGATORIES

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1	2	3
			Excess of Statement
			over Fair Value (-), or Fair Value over
	Statement (Admitted)		Fair Value over
	Value	Fair Value	Statement (+)
31.1 Bonds	81,827,577	81,348,004	(479,573)
31.2 Preferred stocks			
31.3 Totals	81,827,577	81,348,004	(479,573)

31.4	1.4 Describe the sources or methods utilized in determining the fair values: The Plan's investment manager New England Asset Management, Inc. (NEAM) uses the following price sources: Reuters, PricingDirect, Markit, ICE, Bloomberg and Best Credit Data to determine fair value.					
32.1	Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?	Yes	. [] [No [X]	
32.2	If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?	Yes	; []	No []	
32.3	If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:					
33.1 33.2	Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed?	Yes	; [X] [No []	
34.	By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security: a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available. b. Issuer or obligor is current on all contracted interest and principal payments. c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal.					
	Has the reporting entity self-designated 5GI securities?	Yes	; [] [No [X]	
35.	By self-designating PLGI securities, the reporting entity is certifying its compliance with the requirements as specified in the Purposes and Procedures Manual of the NAIC Investment Analysis Office (P&P Manual) for private letter rating (PLR) securities and the following elements of each self-designated PLGI security: a. The security was either:					
	 i. issued prior to January 1, 2018 (which is exempt from PLR filing requirements pursuant to the P&P Manual), or ii. issued from January 1, 2018 to December 31, 2021 and subject to a confidentiality agreement executed prior to January 1, 2022 which confidentiality agreement remains in force, for which an insurance company cannot provide a copy of a private letter rating rationale report to the SVO due to confidentiality or other contractual reasons ("waived submission PLR securities"). b. The reporting entity is holding capital commensurate with the NAIC Designation and NAIC Designation Category reported for the security. 					
	 c. The NAIC Designation and NAIC Designation Category were derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating, dated during the financial statement year, held by the insurer and available for examination by state insurance regulators. d. Other than for waived submission PLR securities, defined above, on or after January 1, 2024 for any PLR securities issued on or after January 1, 2022, if the reporting entity is not permitted to share this private credit rating or the private rating letter rationale report of the 					
	PL security with the SVO, it certifies that it is reporting it as an NAIC 5.B GI and may not assign any other self-designation. Has the reporting entity self-designated PLGI to securities, all of which meet the above requirement and as specified in the P&P Manual?	Yes	; [] !	No [X]	
36.	By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund: a. The shares were purchased prior to January 1, 2019.		•			
	 b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019. d. The fund only or predominantly holds bonds in its portfolio. e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO. f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed. 					
	Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?	Yes	; []	No [X]	
37.	By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following: a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date. b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties. c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for					
	which documentation is available for regulator review. d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a - 37.c are reported as long-term investments. Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria?	1 '	1 nk	у 1	Ν/Δ Γ	1
	rias die reporting endry folieure newed short-term of dash equivalent investifients in accordance with these chiefla?	1 1	io [ν]	IN/IL	1

38.1	8.1 Does the reporting entity directly hold cryptocurrencies?							
38.2	If the response to 38.1 is yes, on what schedule are they reported?							
39.1	Does the reporting entity directly or indirectly accept cryptocurrencies as payments for p	oremiums on policies?		Yes [] No [X]			
39.2		ately converted to U.S. doll] No []] No []			
39.3	If the response to 38.1 or 39.1 is yes, list all cryptocurrencies accepted for payments of	premiums or that are held	directly.					
	1 Name of Cryptocurrency	2 Immediately Converted to USD, Directly Held, or Both	3 Accepte Paymer Premiu	nt of				
40.1 40.2	OTHER Amount of payments to trade associations, service organizations and statistical or rating List the name of the organization and the amount paid if any such payment represented service organizations, and statistical or rating bureaus during the period covered by this	ا 25% or more of the total			19 , 160			
	1		2					
	Name		Amount Paid					
	Federation of lowa Insurers		18,000					
41.1	Amount of payments for legal expenses, if any?			\$	1 , 189 , 197			
41.2	.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for legal expenses during the period covered by this statement.							
	1 Name		2 Amount Paid					
	Natife		AIIIOUIIL F aiu					
42.1	Amount of payments for expenditures in connection with matters before legislative bodi	es, officers, or department	s of government, if a	ny?\$				
42.2	List the name of the firm and the amount paid if any such payment represented 25% or connection with matters before legislative bodies, officers, or departments of governments.							
	1 Name		2 Amount Paid					
	nume		, dilit i did					

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1 1.2	Does the reporting entity have any direct Medicare Supplement Insurance in force? If yes, indicate premium earned on U.S. business only.					
1.3	What portion of Item (1.2) is not reported on the Medicare Supplement Insul 1.31 Reason for excluding	rance Experience Exhibit?	\$			
1.4	Indicate amount of earned premium attributable to Canadian and/or Other A	slien not included in Item (1.2) above	\$			
1.5	Indicate total incurred claims on all Medicare Supplement Insurance		\$			
1.6	Individual policies:	Most current three years:				
		1.61 Total premium earned	\$			
		1.62 Total incurred claims				
		1.63 Number of covered lives				
		All years prior to most current three years:				
		1.64 Total premium earned	¢.			
		1.65 Total incurred claims				
			· ·			
		1.66 Number of covered lives				
4 7	Orange audicines	Mark surrout there are seen				
1.7	Group policies:	Most current three years:	_			
		1.71 Total premium earned				
		1.72 Total incurred claims	\$			
		1.73 Number of covered lives				
		All years prior to most current three years:				
		1.74 Total premium earned	\$			
		1.75 Total incurred claims	\$			
		1.76 Number of covered lives				
2.	Health Test:					
		1 2				
		Current Year Prior Year				
	2.1 Premium Numerator					
	2.2 Premium Denominator					
	2.3 Premium Ratio (2.1/2.2)					
	2.4 Reserve Numerator					
	2.5 Reserve Denominator					
	2.6 Reserve Ratio (2.4/2.5)					
	2.0 1.000170 1.000 (2. 112.0)					
3.2	Has the reporting entity received any endowment or gift from contracting hor returned when, as and if the earnings of the reporting entity permits?		Yes [] No [X]			
4.1	Have copies of all agreements stating the period and nature of hospitals', pl	nysicians', and dentists' care offered to subscribers and				
	dependents been filed with the appropriate regulatory agency?		Yes [X] No []			
4.2	If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do	-	Yes [] No []			
5.1	Does the reporting entity have stop-loss reinsurance?		Yes [] No [X]			
5.2	If no, explain: There is no state or program requirement for reinsurance. The Parent has s reinsurance.					
5 °	Maximum ratained risk (see instructions)	5.31 Comprehensive Medical	¢ 0,000,000			
5.3	Maximum retained risk (see instructions)					
		5.32 Medical Only5.33 Medicare Supplement				
		• • • • • • • • • • • • • • • • • • • •				
		5.34 Dental & Vision				
		5.35 Other Limited Benefit Plan	•			
6.	Describe arrangement which the reporting entity may have to protect subscr		\$			
	hold harmless provisions, conversion privileges with other carriers, agreeme agreements: There is no state or program requirement for reinsurance. The Parent has s reinsurance.	ufficient capital to fund potential losses that would be covered by				
7.1	Does the reporting entity set up its claim liability for provider services on a s		Yes [X] No []			
7.2	If no, give details					
8.	Provide the following information regarding participating providers:	8.1 Number of providers at start of reporting year 8.2 Number of providers at end of reporting year .				
9.1	Does the reporting entity have business subject to premium rate guarantees	5?	Yes [] No [X]			
9.2	If yes, direct premium earned:	9.21 Business with rate guarantees between 15-36 months 9.22 Business with rate guarantees over 36 months				

10.1	Does the reporting entity have Incentive Pool, Withh	nold or Bonus Ar	rangements in its p	provider contracts	?		. Yes [X]	No []
10.2	10.2 If yes: 10.21 Maximum amount payable bo 10.22 Amount actually paid for year 10.23 Maximum amount payable wit 10.24 Amount actually paid for year						\$	3,491,600
11.1	Is the reporting entity organized as:			11.13 An Indiv	al Group/Staff Mode dual Practice Asso Model (combination	ciation (IPA), or,	Yes [X]] No [X]] No []] No [X]
11.2 11.3 11.4	Is the reporting entity subject to Statutory Minimum of tyes, show the name of the state requiring such mill fyes, show the amount required.	nimum capital ar	nd surplus				\$	No [] lowa 1,000,000
11.5 11.6	Is this amount included as part of a contingency result the amount is calculated, show the calculation	erve in Stockhoid	iers equity?				res []	No [X]
12.	List service areas in which reporting entity is license	ed to operate:						
			1 Name of Service	e Area				
13.1	Do you act as a custodian for health savings accour	nts?					. Yes []	No [X]
13.2	If yes, please provide the amount of custodial funds	held as of the re	porting date				\$	
13.3	Do you act as an administrator for health savings ac	counts?					Yes []	No [X]
13.4	If yes, please provide the balance of funds administration	ered as of the re	porting date				\$	
14.1 14.2	Are any of the captive affiliates reported on Schedul If the answer to 14.1 is yes, please provide the follow		orized reinsurers?			Yes [] No [] N/A [X]
	1	2	3	4		Supporting Reserv		
	Company Name	NAIC Company Code	Domiciliary Jurisdiction	Reserve Credit	5 Letters of Credit	6 Trust Agreements	7 Other	
15.	Provide the following for individual ordinary life insurceded):	rance* policies (l	J.S. business only) for the current ye		ance assumed or	<u></u>	<u></u>
				15.2	Direct Premium Wri Fotal Incurred Clain Number of Covered	ns	\$	
		*Ordir	nary Life Insurance	Includes				
	Term(whether full und Whole Life (whether full whole Life (whether full und Whole (whether full u							
	Variable Life (with or			ig, jet issue, siloi	топп арр)			
	Universal Life (with o Variable Universal Life			antee)				
16.	Is the reporting entity licensed or chartered, register	ed, qualified, eliç	lible or writing busi	ness in at least tw	o states?		Yes [] No	lo [X]
16.1	If no, does the reporting entity assume reinsurance domicile of the reporting entity?						Yes [] No	lo [X]

FIVE-YEAR HISTORICAL DATA

			10.014.07			
		1 2024	2 2023	3 2022	4 2021	5 2020
	Balance Sheet (Pages 2 and 3)					
1.	Total admitted assets (Page 2, Line 28)	369,403,436	242,216,795	1,013,976	1,000,000	
2.	Total liabilities (Page 3, Line 24)	198,588,193	168,940,570			
3.	Statutory minimum capital and surplus requirement	1,000,000	1,000,000	1,000,000	1,000,000	
4.	Total capital and surplus (Page 3, Line 33)	170,815,243		1,013,976	1,000,000	
	Income Statement (Page 4)					
5.	Total revenues (Line 8)	1,512,884,014	633,982,781			
6.	Total medical and hospital expenses (Line 18)		590,772,654			
7.	Claims adjustment expenses (Line 20)	46,993,166	20,784,139			
8.	Total administrative expenses (Line 21)	82,054,718		1,296		
9.	Net underwriting gain (loss) (Line 24)					
10.	Net investment gain (loss) (Line 27)					
11.	Total other income (Lines 28 plus 29)					
12.	Net income or (loss) (Line 32)					
	Cash Flow (Page 6)	, , , , , ,	, , , , , ,			
13.	Net cash from operations (Line 11)	30 633 393	125 365 110	(1 296)		
10.	Risk-Based Capital Analysis		120,000,110	(1,200)		
14.	Total adjusted capital	170 815 243	73 276 225	1 013 976	1 000 000	
15.	Authorized control level risk-based capital					
10.	Enrollment (Exhibit 1)		20,004,400	1,000		
16.	Total members at end of period (Column 5, Line 7).	100 203	170 929			
17.	Total members months (Column 6, Line 7)					
17.	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0	2,007,004				
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)					
20.	Cost containment expenses	2.8	3.0			
21.	Other claims adjustment expenses	0.3	0.3			
22.	Total underwriting deductions (Line 23)	94.8	101.5			
23.	Total underwriting gain (loss) (Line 24)	5.2	(1.5)			
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 17, Col. 5)	137,382,718				
25.	Estimated liability of unpaid claims-[prior year (Line 17, Col. 6)]	157,889,363				
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)					
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)					
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)					
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)					
30.	Affiliated mortgage loans on real estate					
31.	All other affiliated					
32.	Total of above Lines 26 to 31					
33.	Total investment in parent included in Lines 26 to					
UOTE.	31 above. If a party to a merger, have the two most recent years	. 6 (1.1)		10.00	.1	


	31 above.								
NOTE:	E: If a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure								
	requirements of SSAP No. 3, Accounting Changes and Correction of Errors?							No []
	If no, please explain:								

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories

			1		Allocat	ed by States		rect Business O	nlı			
			'	2	3	4	5	6 Federal Employees	7 Life and	8	9	10
	States, etc.		Active Status	Accident and Health	Medicare	Medicaid	CHIP Title	Health Benefits Program	Annuity Premiums & Other	Property/ Casualty Premiums	Total Columns 2	Deposit-Type
1.	Alabama	ΛΙ	(a) N	Premiums	Title XVIII	Title XIX	XXI	Premiums	Considerations	Premiums	Through 8	Contracts
2.	Alaska		N									
		AZ	N									
4.		AR	N									
5.		CA	N									
6.	Colorado	СО	N									
7.		CT	N									
8.	Delaware	DE	N									
9.	District of Columbia	DC	N									
10.	Florida	FL	N									
11.	Georgia	GA	N									
12.	Hawaii	HI	N									
		ID	N									
14.	Illinois	IL	N									
		IN	N									
		IA	L			1,470,426,964	42,457,050				1,512,884,014	
		KS	N									
18.	=	KY	N									
	Louisiana		N									
		ME	N									
	-	MD	N									
		MA	N									
	_	MI	N									
		MN	N									
	• • •	MS	N									
		MO	N									
		MT	N									
		NE	N									
		NV	N									
	•	NH	N									
	New Jersey		N N									
	New Mexico											
		NY	N N									
	North Carolina North Dakota		N									
36.		ND OH	N									
		OK	N									
38.		OR	N									
	Pennsylvania		N									
40.	•	RI	N									
	South Carolina		N									
		SD	N									
		TN	N									
44.	Texas		N									
45.	Utah	UT	N									
	Vermont		N									
47.	Virginia	VA	N									
	Washington		N									
49.	West Virginia	WV	N									
	Wisconsin		N									
	Wyoming		N									
	American Samoa	-	N									
		GU	N									
	Puerto Rico		N									
	U.S. Virgin Islands	VI	N									
56.	Northern Mariana	MD	N									
57.	Islands	MP CAN	N									
	Aggregate Other	CAIN	IV	•••••	•••••						•••••	
00.	Aliens	ОТ	XXX									
59.	Subtotal		XXX			1,470,426,964	42,457,050				1,512,884,014	
60.	Reporting Entity Contributions for Em	nployee					. ,					
64	Benefit Plans		XXX			1 470 400 004	40 457 050				1 510 004 044	
61.	Totals (Direct Busines		XXX			1,470,426,964	42,457,050				1,512,884,014	
59004	DETAILS OF WRITE		V0.01									
58001. 58002.			XXX									
58002. 58003.			XXX									
	Summary of remainin		XXX									
JU330.	write-ins for Line 58 fr											
	overflow page		XXX									
58999.	Totals (Lines 58001 t	hrough										
	58003 plus 58998)(Li	ne 58	V0.01									
(=) A =4:	above) e Status Counts:		XXX			<u> </u>	<u> </u>	<u> </u>	<u> </u>		1	1

(a)	Active	Status	Counts:



Continued on

Page 2

NC

100%

(HMO)

100%


100%

CA

CA

100%

NAIC: 17290 (HMO)



OVERFLOW PAGE FOR WRITE-INS

NONE